fluorouracil has been researched along with Sensitivity and Specificity in 232 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the clinical response of keloidal and hypertrophic scars after treatment with intralesional corticosteroid alone or combined with 5-fluorouracil (5-FU), 5-FU alone, and the 585-nm flashlamp-pumped pulsed-dye laser (PDL)." | 9.10 | Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. ( Fitzpatrick, RE; Manuskiatti, W, 2002) |
| "No significant difference was detected between the treatment with mitoxantrone as a single agent and the combination of low-dose FEC in terms of response or survival; therefore, the imperative of the necessity of first-line combination chemotherapy for patients with high-risk metastatic breast cancer may be questioned." | 9.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure." | 9.09 | Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. ( Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C, 2000) |
| "The cumulative pharmacokinetic pattern of oxaliplatin, a new diamminecyclohexane platinum derivative, was studied in patients with metastatic colorectal cancer." | 9.08 | Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ( Allain, P; Boisdron-Celle, M; Bouil, AL; Brienza, S; Cailleux, A; Cvitkovic, E; Delva, R; Gamelin, E; Krikorian, A; Larra, F; Robert, J; Turcant, A, 1997) |
| " In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide+ methotrexate+fluorouracil has been reported to improve survival in comparison with patients who are not given this treatment." | 9.08 | Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer. ( Becagli, P; Messori, A; Tendi, E; Trippoli, S, 1996) |
| "We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer." | 8.86 | A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. ( Chen, ML; Dai, LH; Fang, CH; Liang, LS; Wang, XK, 2010) |
| "Our data provide the molecular-based evidence for the observed clinical benefits of adding 5-fluorouracil to a steroid injection for improved scar regression and reduced recurrence of keloids." | 7.79 | A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblasts in vitro. ( Burd, A; Cai, YJ; Huang, L; Leung, BC; Lung, I, 2013) |
| "Sequential administration of paclitaxel plus combined fluorouracil, epirubicin, and cyclophosphamide (P-FEC) is 1 of the most common neoadjuvant chemotherapies for patients with primary breast cancer and produces pathologic complete response (pCR) rates of 20% to 30%." | 7.77 | Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. ( Baba, Y; Kim, SJ; Kishi, K; Naoi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanei, T; Tominaga, N; Tsunashima, R, 2011) |
| "A recent clinical trial demonstrated that the addition of lapatinib to capecitabine in the treatment of HER-2-positive advanced breast cancer (ABC) significantly increases median time to progression." | 7.75 | Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. ( Hay, JW; Le, QA, 2009) |
| "A wireless sensing device was developed for the in-situ monitoring of the growth of human breast cancer cells (MCF-7) and evaluation of the cytotoxicity of the anticancer drugs fluorouracil and cisplatin." | 7.74 | In-situ monitoring of breast cancer cell (MCF-7) growth and quantification of the cytotoxicity of anticancer drugs fluorouracil and cisplatin. ( Cai, Q; Grimes, CA; Guo, M; Li, Q; Xiao, X; Yao, S, 2008) |
| " Here human gastric adenocarcinoma (AGS) cells were treated with lethal dose 10 and 50 (LD(10) and LD(50)), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer." | 7.74 | [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. ( Park, KG; Smith, TA; Suttie, SA, 2007) |
| "The level of the enzyme thymidylate synthase (TS) is known to inversely correlate with the clinical activity of 5-fluorouracil (FU) in advanced colorectal cancer patients." | 7.72 | Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. ( Aschele, C; Belvedere, O; Cataldi, P; Di Loreto, C; Guglielmi, A; Puglisi, F; Sobrero, A, 2004) |
| "TS levels were measured immunohistochemically on archival specimens of colorectal cancer metastases from 124 patients homogeneously treated in a series of clinical trials at our institutions with: (A) leucovorin (LV)-modulated infusional 5-FU (n = 48); (B) LV-modulated bolus 5-FU (n = 41); (C) methotrexate (MTX)-modulated bolus 5-FU (n = 35)." | 7.71 | Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. ( Aschele, C; Bandelloni, R; Barni, S; Cascinu, S; Catalano, V; Debernardis, D; Drudi, G; Gallo, L; Giordani, P; Lonardi, S; Maley, F; Monfardini, S; Turci, D, 2002) |
| "To perform an economic evaluation of the joint use of 5-fluorouracil and levamisole as adjuvant chemotherapy in patients with fully resected Dukes' Stage C carcinoma of the colon, compared with resection and no chemotherapy." | 7.68 | A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. ( Gurney, H; Hall, J; Harnett, PR; Smith, RD, 1993) |
| "Thirteen patients with previously untreated squamous cell carcinoma of the hypopharynx, T3 or T4, were included." | 6.71 | Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. ( Agostini, D; Babin, E; Bequignon, A; Chesnay, E; Constans, JM; Moreau, S; Regeasse, A; Sobrio, F, 2003) |
| "Our cohort (n = 25) included patients with advanced and aggressive breast cancers, who underwent neoadjuvant therapy with the CAF regimen (cyclophosphamide, doxorubicin, fluorouracil)." | 5.16 | Localization of PKCη in cell membranes as a predictor for breast cancer response to treatment. ( Abu-Ghanem, S; Ariad, S; Karp, G; Livneh, E; Mermershtain, W; Novack, V; Sion-Vardy, N, 2012) |
| "This trial compares a non-taxane regimen (fluorouracil, epirubicin, and cyclophosphamide [FEC] for six cycles) with a taxane regimen (docetaxel for three cycles followed by epirubicin plus docetaxel [TET] for three cycles) in women with oestrogen-receptor-negative breast cancer." | 5.12 | Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. ( Acharya, CR; André, S; Becette, V; Bergh, J; Blot, E; Bonnefoi, H; Cameron, D; Campone, M; Delorenzi, M; Farmer, P; Iggo, RD; Jassem, J; Mauriac, L; Mukherjee, S; Nevins, JR; Petit, T; Potti, A; Rouanet, P; Tubiana-Hulin, M, 2007) |
| "We evaluated quantitative measurement series (MS) with 18F-FDG and PET and compared different quantification methods for prediction of individual survival in patients with metastatic colorectal cancer receiving chemotherapy with 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX)." | 5.11 | Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. ( Burger, C; Dimitrakopoulou-Strauss, A; Irngartinger, G; Rudi, J; Rühl, A; Strauss, LG; Stremmel, W, 2004) |
| "5-Fluorouracil (5-FU), an antitumor agent, is used clinically against a variety of malignancies, including bladder carcinoma." | 5.11 | Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. ( Fukushima, M; Li, YN; Miki, T; Mizutani, Y; Nakanishi, H; Wada, H; Yoshida, O, 2004) |
| "To compare the clinical response of keloidal and hypertrophic scars after treatment with intralesional corticosteroid alone or combined with 5-fluorouracil (5-FU), 5-FU alone, and the 585-nm flashlamp-pumped pulsed-dye laser (PDL)." | 5.10 | Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. ( Fitzpatrick, RE; Manuskiatti, W, 2002) |
| "Pulmonary toxicity was prospectively evaluated within a randomized trial for breast cancer patients at high risk for relapse, who postoperatively received as adjuvant therapy either 9 cycles of tailored chemotherapy (20 patients) (cyclophosphamide, epirubicin, 5-fluorouracil [FEC]) or standard FEC x 3 followed by high-dose chemotherapy (cyclophosphamide, thiotepa, carboplatin [CTCb]) supported by peripheral blood stem cell transplantation (14 patients)." | 5.10 | Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. ( Bergh, J; Blomqvist, C; Hernberg, M; Keyriläinen, J; Maasilta, P; Virkkunen, P; Wiklund, T, 2002) |
| "No significant difference was detected between the treatment with mitoxantrone as a single agent and the combination of low-dose FEC in terms of response or survival; therefore, the imperative of the necessity of first-line combination chemotherapy for patients with high-risk metastatic breast cancer may be questioned." | 5.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure." | 5.09 | Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. ( Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C, 2000) |
| " We performed a pharmacoeconomic evaluation of the ability of dexrazoxane to prevent cardiac-related adverse events in patients with Stage IIIB or IV metastatic breast cancer who were treated with a median of 10 cycles of intravenous FAC (5-fluorouracil, doxorubicin and cyclophosphamide) at doses of 500/50/500 mg/m2 respectively." | 5.08 | Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation. ( Arundell, E; Bates, M; Lieu, D; Tonkin, K; Williamson, T; Zagari, M, 1996) |
| " In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide+ methotrexate+fluorouracil has been reported to improve survival in comparison with patients who are not given this treatment." | 5.08 | Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer. ( Becagli, P; Messori, A; Tendi, E; Trippoli, S, 1996) |
| "The cumulative pharmacokinetic pattern of oxaliplatin, a new diamminecyclohexane platinum derivative, was studied in patients with metastatic colorectal cancer." | 5.08 | Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ( Allain, P; Boisdron-Celle, M; Bouil, AL; Brienza, S; Cailleux, A; Cvitkovic, E; Delva, R; Gamelin, E; Krikorian, A; Larra, F; Robert, J; Turcant, A, 1997) |
| "We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer." | 4.86 | A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. ( Chen, ML; Dai, LH; Fang, CH; Liang, LS; Wang, XK, 2010) |
| "Combination therapy of tegafur/uracil (UFT) and leucovorin (LV) is widely used to treat colorectal cancers." | 4.02 | Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy. ( Endo, Y; Hirashita, T; Inomata, M; Itoh, H; Iwao, M; Iwashita, Y; Masuda, T; Shiraiwa, K; Suzuki, Y; Tada, K; Tanaka, R; Uchida, H, 2021) |
| "Our data provide the molecular-based evidence for the observed clinical benefits of adding 5-fluorouracil to a steroid injection for improved scar regression and reduced recurrence of keloids." | 3.79 | A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblasts in vitro. ( Burd, A; Cai, YJ; Huang, L; Leung, BC; Lung, I, 2013) |
| "Sequential administration of paclitaxel plus combined fluorouracil, epirubicin, and cyclophosphamide (P-FEC) is 1 of the most common neoadjuvant chemotherapies for patients with primary breast cancer and produces pathologic complete response (pCR) rates of 20% to 30%." | 3.77 | Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. ( Baba, Y; Kim, SJ; Kishi, K; Naoi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanei, T; Tominaga, N; Tsunashima, R, 2011) |
| "Regimens containing bevacizumab and 5-fluorouracil have achieved substantial progress in the treatment of colorectal cancer." | 3.77 | Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. ( Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Matsuda, K; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "Gene expression profiling was done on fine-needle aspirations of 100 stage I to III breast cancers before preoperative paclitaxel, 5-fluorouracil, doxorubicin, and cyclophosphamide combination chemotherapy." | 3.76 | Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. ( Baggerly, K; Coutant, C; Kim, YC; Lee, JK; Pusztai, L; Qi, Y; Rouzier, R; Symmans, WF; Theodorescu, D, 2010) |
| "Epirubicin, cisplatin or 5-fluorouracil was administered to severe combined immune-deficient mice bearing OE19 oesophageal adenocarcinoma xenografts." | 3.76 | Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. ( Appleyard, V; Baker, L; Exon, D; Kelly, P; Lamont, D; Murray, K; Paulin, F; Suttie, S; Thompson, A, 2010) |
| "The continuation of trastuzumab beyond progression in combination with capecitabine as secondary chemotherapy for HER2-positive metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase in toxicity." | 3.76 | Trastuzumab beyond progression: a cost-utility analysis. ( Brauchli, P; Dedes, KJ; Matter-Walstra, KW; Pestalozzi, BC; Schwenkglenks, M; Szucs, TD, 2010) |
| "A recent clinical trial demonstrated that the addition of lapatinib to capecitabine in the treatment of HER-2-positive advanced breast cancer (ABC) significantly increases median time to progression." | 3.75 | Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. ( Hay, JW; Le, QA, 2009) |
| " Here human gastric adenocarcinoma (AGS) cells were treated with lethal dose 10 and 50 (LD(10) and LD(50)), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer." | 3.74 | [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. ( Park, KG; Smith, TA; Suttie, SA, 2007) |
| "A wireless sensing device was developed for the in-situ monitoring of the growth of human breast cancer cells (MCF-7) and evaluation of the cytotoxicity of the anticancer drugs fluorouracil and cisplatin." | 3.74 | In-situ monitoring of breast cancer cell (MCF-7) growth and quantification of the cytotoxicity of anticancer drugs fluorouracil and cisplatin. ( Cai, Q; Grimes, CA; Guo, M; Li, Q; Xiao, X; Yao, S, 2008) |
| "The effect of tacrolimus (FK506) and 5-fluorouracil (5-FU) on hepatocellular carcinoma remains elusive." | 3.73 | Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721. ( Cao, XW; Ding, GS; Fu, ZR, 2005) |
| "We investigated relapse-free (RFS), breast cancer-corrected (BCCS) and overall survival (OS) related to TP53 status in node-positive breast cancer patients that had received polychemotherapy [cyclophosphamide, methotrexate, 5-fluorouracil (CMF)] and/or endocrine therapy (tamoxifen)." | 3.73 | Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. ( Andersson, J; Bergh, J; Carlsson, G; Gustavsson, B; Holmberg, L; Inganäs, M; Klaar, S; Larsson, L; Nilsson, J; Ohd, J; Rudenstam, CM, 2005) |
| "The level of the enzyme thymidylate synthase (TS) is known to inversely correlate with the clinical activity of 5-fluorouracil (FU) in advanced colorectal cancer patients." | 3.72 | Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. ( Aschele, C; Belvedere, O; Cataldi, P; Di Loreto, C; Guglielmi, A; Puglisi, F; Sobrero, A, 2004) |
| "Adjuvant chemotherapy with 5-fluorouracil (5-FU) and mitomycin C (MMC) has commonly been used after resection of colorectal cancer." | 3.71 | The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer. ( Hashimoto, Y; Minami, K; Ueda, K; Watatani, M, 2001) |
| "TS levels were measured immunohistochemically on archival specimens of colorectal cancer metastases from 124 patients homogeneously treated in a series of clinical trials at our institutions with: (A) leucovorin (LV)-modulated infusional 5-FU (n = 48); (B) LV-modulated bolus 5-FU (n = 41); (C) methotrexate (MTX)-modulated bolus 5-FU (n = 35)." | 3.71 | Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. ( Aschele, C; Bandelloni, R; Barni, S; Cascinu, S; Catalano, V; Debernardis, D; Drudi, G; Gallo, L; Giordani, P; Lonardi, S; Maley, F; Monfardini, S; Turci, D, 2002) |
| " In order to evaluate the HDRA with the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide end point for clinical use, chemosensitivity to mitomycin C, doxorubicin, 5-fluorouracil, and cisplatin of 107 advanced gastric and 109 advanced colorectal cancers was determined in vitro in a correlative clinical trial." | 3.69 | Clinical applications of the histoculture drug response assay. ( Furukawa, T; Hoffman, RM; Kubota, T, 1995) |
| "To perform an economic evaluation of the joint use of 5-fluorouracil and levamisole as adjuvant chemotherapy in patients with fully resected Dukes' Stage C carcinoma of the colon, compared with resection and no chemotherapy." | 3.68 | A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. ( Gurney, H; Hall, J; Harnett, PR; Smith, RD, 1993) |
| "However, the role of MRI in restaging rectal tumors after neoadjuvant CRT is contentious." | 2.79 | Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10-01 and 11-02. ( Baek, JY; Chie, EK; Jang, HS; Jung, JH; Kim, DY; Kim, HC; Kim, JG; Kim, SY; Kim, TH; Lee, JH; Lee, MA; Nam, TK; Oh, JH; Oh, ST; Park, HC; Park, SC, 2014) |
| "59 cases of advanced gastric cancer were enrolled." | 2.78 | Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer. ( Ji, M; Jiang, JT; Li, XD; Wu, CP; Wu, J; Xu, B; Zhang, HY; Zhao, WQ; Zhou, WJ, 2013) |
| "The presence of residual tumour by conventional imaging, dichotomised as positive or negative, and the level of FDG uptake (standardised uptake values, SUV) were compared with histopathology, which served as the reference standard." | 2.75 | Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. ( Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C, 2010) |
| "Oral capecitabine (Xeloda) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer." | 2.72 | Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. ( Beham, A; Bertetto, O; Bustová, I; Cassidy, J; Cowell, W; Coxon, F; Díaz-Rubio, E; Douillard, JY; Dufour, P; Figer, A; Fountzilas, G; Garrison, LP; Jelic, S; Johnston, PG; Lesniewski-Kmak, K; Malzyner, A; Maughan, TS; McKendrick, JJ; Patel, KK; Scheithauer, W; Twelves, C, 2006) |
| "Twenty patients with squamous cell carcinoma (SCC) of the head and neck were included in the study." | 2.71 | FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. ( Kitagawa, Y; Nakamura, M; Nishizawa, S; Ogasawara, T; Sadato, N; Sano, K; Yonekura, Y, 2003) |
| "Thirteen patients with previously untreated squamous cell carcinoma of the hypopharynx, T3 or T4, were included." | 2.71 | Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. ( Agostini, D; Babin, E; Bequignon, A; Chesnay, E; Constans, JM; Moreau, S; Regeasse, A; Sobrio, F, 2003) |
| "Capecitabine/docetaxel was a cost-effective treatment in patients with anthracycline-pretreated advanced breast carcinoma, and had an incremental cost-effectiveness ratio that compares very favorably with that of many other oncology therapies." | 2.71 | Capecitabine plus docetaxel combination therapy. ( Hornberger, J; Jamieson, C; Jones, S; Maraninchi, D; Martín, M; McKendrick, J; Miles, D; O'Shaughnessy, J; Twelves, C; Verma, S, 2005) |
| "Seventeen patients with stage II breast cancer were included." | 2.69 | The relationship between serum levels of erythropoietin (EPO) and insulin-like growth factor-1 (ILGF-1) and hematocrit (HCT) in breast cancer patients receiving non-nephrotoxic chemotherapy. ( Habbal, Z; Ibrahim, K; Kahwaji, S; Khalil, A; Medawar, W; Seoud, M; Shamseddine, A, 1998) |
| "Stage II breast cancer patients who were or became node negative by both ultrasonographic and physical examinations after IC had a 48% incidence of nodal metastases." | 2.69 | The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. ( Ames, FC; Bedi, D; Buzdar, AU; Feig, BW; Fornage, BD; Hunt, KK; Lenert, JT; Mirza, NQ; Ross, MI; Singletary, SE; Tolley, SM; Vlastos, G; Winchester, DJ, 2000) |
| "In 5-FU-based cancer chemotherapy, severe toxicities were observed at higher rates in patients who were heterozygous for a mutant DPYD allele, compared with toxicities in patients who were homozygous for the wild DPYD allele." | 2.42 | Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. ( Omura, K, 2003) |
| "The antitumor activity of most anticancer agents is limited by a number of different factors, such as their cellular targets and activating enzymes, while constitutive genetic polymorphisms may limit drug bioavailability and influence either antitumor efficacy or toxic side effects." | 2.42 | Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. ( Peters, GJ; Smorenburg, CH; Van Groeningen, CJ, 2004) |
| "EUS is an unreliable tool for staging esophageal cancer after NAC." | 1.39 | Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis. ( Domagk, D; Domschke, W; Heinzow, HS; Kucharzik, T; Meister, T; Seifert, H; Tsepetonidis, S; Wolters, H, 2013) |
| " Combined quantification of U and UH(2) with 5-FU and 5-FUH(2) may provide a pre-therapeutic assessment of DPD activity and further guide drug dosing during therapy." | 1.39 | LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. ( Amstutz, U; Büchel, B; Bühr, C; Largiadèr, CR; Rhyn, P; Schürch, S, 2013) |
| " To explain such interactions, a pharmacokinetic study was designed." | 1.39 | Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine. ( Ganti, V; Nagar, S; Walker, EA, 2013) |
| "One hundred and twenty-eight advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine in Peking University Cancer Hospital from December 2006 to October 2010 were enrolled in the study." | 1.38 | Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. ( Gao, J; Li, Y; Lu, Z; Shen, L; Yu, J, 2012) |
| "At pretreatment assessment, anal cancer was identified by PET-CT in 47 patients (88." | 1.38 | Role of positron emission tomography-computed tomography in the management of anal cancer. ( Baccega, M; Bellò, M; Cassoni, P; Cravero, F; Filippini, C; Fora, G; Lesca, A; Milanesi, E; Mistrangelo, M; Morino, M; Munoz, FH; Pelosi, E; Racca, P; Ricardi, U; Skanjeti, A, 2012) |
| "Tegafur is a 5-fluorouracil (5-FU) prodrug widely used outside the United States to treat colorectal cancer as well as cancers of the head and neck." | 1.38 | Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ( Hurwitz, HI; McManus, TJ; Peer, CJ; Petros, WP, 2012) |
| "A total of 38 T3-4/N+ rectal cancer patients received capecitabine-oxaliplatin and radiotherapy followed by surgery." | 1.38 | A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. ( Carlomagno, C; D'Incalci, M; De Placido, S; De Stefano, A; Della Vittoria Scarpati, G; Falcetta, F; Marchini, S; Pepe, S; Singh, VK; Ubezio, P, 2012) |
| "The finding that some rectal cancers respond to neoadjuvant chemoradiation is broadening new surgical options for the treatment of some of these tumors that, until now, required a total mesorectal excision." | 1.37 | Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? ( Arbea, L; Aristu, J; Baixauli, J; Beorlegui, C; Hernandez-Lizoain, JL; Pastor, C; Sola, J; Subtil, JC, 2011) |
| "Forty-one patients with newly diagnosed esophageal cancer treated with combined radiochemotherapy were included in this study." | 1.37 | Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. ( Albarghach, N; Corcos, L; Hatt, M; Le Rest, CC; Metges, JP; Pradier, O; Tixier, F; Visvikis, D, 2011) |
| "Forty-seven patients with head and neck cancers who underwent definitive chemoradiotherapy between December 1998 and March 2006 were reviewed retrospectively." | 1.36 | Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers. ( Kadoya, M; Koiwai, K; Sasaki, S; Shikama, N; Shinoda, A, 2010) |
| " Such variability, which may lead to treatment failure or toxicity, could need drug concentration measurement to individualize dosing regimen." | 1.36 | An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma. ( Bérard, M; Demarchi, M; Kantelip, JP; Montange, D; Muret, P; Piédoux, S; Royer, B, 2010) |
| "The risk of venous thromboembolism has been reported to increase when receiving bevacizumab." | 1.36 | Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. ( Doi, T; Fuse, N; Ikematsu, H; Kaneko, K; Koike, K; Kojima, T; Minashi, K; Mochizuki, S; Ohtsu, A; Tahara, M; Yano, T; Yoshino, T, 2010) |
| "5-fluorouracil (5-FU) has been one of the most widely used chemotherapeutic agents to treat various tumors, and eniluracil (5-ethynyluracil or EU) is being developed as a novel modulator of 5-FU." | 1.36 | Determination of eniluracil and 5-fluorouracil in human plasma by LC-MS/MS. ( Chen, J; Zhou, M, 2010) |
| "Human pancreatic cancer cells such as PANC-1 are known to exhibit marked tolerance to nutrition starvation that enables them to survive for prolonged period of time even under extremely nutrient-deprived conditions." | 1.35 | Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition. ( Awale, S; Esumi, H; Kadota, S; Li, F; Onozuka, H; Tezuka, Y, 2008) |
| "The inhibition rate of gastric cancer by 5-FU (29." | 1.35 | [Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer]. ( Chen, G; Fu, LW; Keshari, RP; Liang, YJ; Yuan, SQ; Zhang, LY; Zhou, ZW, 2009) |
| "In patients with locally advanced rectal cancer (LARC) staging and, after preoperative chemo-radiation therapy (CRT), restaging workup could be useful to tailor therapeutic approaches." | 1.35 | The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. ( Banti, E; Bianchini, E; Capirci, C; Crepaldi, G; Del Favero, G; Facci, E; Galeotti, F; Gava, M; Marano, G; Panzavolta, R; Pasini, F; Rampin, L; Rubello, D, 2009) |
| " In this work, an artificial receptor in the format of molecularly imprinted polymer (MIP) brush 'grafted to' the surface of sol-gel immobilized on cost-effective homemade solid-phase microextraction (SPME) fibers, individually imprinted with either of Ura and 5FU, was used in combination with a voltammetric sensor duly modified with the same MIP." | 1.35 | Ultratrace analysis of uracil and 5-fluorouracil by molecularly imprinted polymer brushes grafted to silylated solid-phase microextraction fiber in combination with complementary molecularly imprinted polymer-based sensor. ( Patel, AK; Prasad, BB; Sharma, PS; Singh, M; Srivastava, S; Tiwari, K, 2009) |
| "A 55-year-old man with advanced gastric cancer underwent total gastrectomy (T3N0M0, stage II , por, sig) in the USA." | 1.34 | [A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel]. ( Akiyama, J; Hayashi, Y; Iwashita, R; Kobayakawa, M; Masaki, N; Nagaoki, Y; Nagata, N; Nozaki, Y; Oshima, T; Sako, A; Sakurai, T; Tamegai, Y; Uemura, N; Umeda, N; Watanabe, M; Yago, Y, 2007) |
| "The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies." | 1.34 | The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. ( Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E, 2007) |
| "Only about 50% of metastatic breast cancer patients benefit from cytotoxic chemotherapy." | 1.33 | Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. ( Brünner, N; Christensen, IJ; Foekens, JA; Holten-Andersen, MN; Look, MP; Meijer-van Gelder, ME; Mouridsen, HT; Schrohl, AS, 2006) |
| "Forty-two patients with invasive breast carcinoma received 4 cycles of anthracycline based neoadjuvant chemotherapy." | 1.33 | Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. ( Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Manavoglu, O; Saraydaroglu, O; Ulukaya, EE, 2006) |
| "Clinical presentation and outcome of breast cancer in our young patients aged under 35 years seems not to be different from that in older patients." | 1.33 | [Breast cancer in young women in the south of Tunisia]. ( Boudawara, T; Daoud, J; Frikha, M; Kallel, F; Khanfir, A; Meziou, M; Mnif, J; Trabelsi, K, 2006) |
| "Capecitabine is an oral fluoropyrimidine carbamate activated sequentially in both liver and tumor tissues by carboxylesterases, cytidine deaminase, and thymidine phosphorylase." | 1.33 | Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes. ( Guichard, SM; Jodrell, DI; Macpherson, JS, 2006) |
| "Recent studies on polychemotherapy of head and neck cancer showed an improved remission rate on adding taxanes to the standard cytotoxic drugs cisplatin and 5-fluorouracil (5-FU)." | 1.33 | EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. ( Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Peters, S; Solbach, C, 2005) |
| "To predict the sensitivity of colorectal cancer to 5-FU, mRNA is extracted from surgically obtained cancer specimens and expression of thymidylate synthetase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), uridine phosphorylase (UP), es-nucleoside transporter (NT), and E2F1 are detected by real-time reverse transcription polymerase chain reaction (RT-PCR) (TaqMan)." | 1.33 | Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil. ( Kubota, T, 2005) |
| "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS)." | 1.33 | Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. ( Clarke, SJ; Li, KM; Rivory, LP, 2005) |
| "To evaluate the effects of the novel protein kinase C (PKC) inhibitor enzastaurin on intracellular phosphoprotein signaling using flow cytometry and to use this approach to measure enzastaurin effects on surrogate target cells taken from cancer patients that were orally dosed with this agent." | 1.33 | Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. ( Basche, M; Britten, CD; Carducci, M; Cook, CA; Eckhardt, SG; Green, LJ; Herbst, RS; Jaken, S; Marder, P; Musib, LC; Ray, C; Thornton, D, 2006) |
| "5-Fluorouracil (5-FU) is a commonly used anti-cancer drug with notable activity in clinical practice, yet it causes significant unpredictable and often serious toxicity." | 1.31 | Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. ( Ackland, SP; Garg, MB; Sakoff, JA; Sevester, JC, 2002) |
| "The prognosis of patients with advanced hepatoma is grim." | 1.31 | Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells. ( Goto, T; Hoshida, Y; Kato, N; Moriyama, M; Omata, M; Otsuka, M; Seki, N; Shiratori, Y; Taniguchi, H, 2002) |
| "Cells derived from human oesophageal squamous cell carcinoma (OSC-1) were grown for 2 days and incubated with cisplatin (CDDP), 5-fluorouracil (5-FU), methotrexate (MTX) or gemcitabine (GEM) for 4 h." | 1.31 | Early changes in [18F]FLT uptake after chemotherapy: an experimental study. ( Bares, R; Bartusek, G; Dittmann, H; Dohmen, BM; Kehlbach, R; Pritzkow, M; Sarbia, M, 2002) |
| "Esophageal cancer is associated with the poorest prognosis among the digestive tract cancers, and chemotherapy is the treatment of choice for many patients." | 1.31 | Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene increases the sensitivity of esophageal cancer cells to 5-fluorouracil. ( Akiyama, S; Fujiwara, M; Hamada, H; Ito, K; Kasai, Y; Nakamura, H; Nakao, A; Sekiguchi, H, 2001) |
| "5-Fluorouracil (5-Fu) is a commonly used anticancer agent for treatment of solid tumours." | 1.31 | Simultaneous HPLC determination of 5-fluorouracil and its metabolites in plasma of cancer patients. ( Berno, E; Canaparo, R; Casale, F; Costa, M; Della Pepa, C; Eandi, M; Muntoni, E; Serpe, L; Zara, GP, 2002) |
| " The method presented here is accurate, precise and sensitive and it has been successfully applied for 5-FU pharmacokinetic investigation and therapeutic drug monitoring." | 1.30 | Simple and sensitive determination of 5-fluorouracil in plasma by high-performance liquid chromatography. Application to clinical pharmacokinetic studies. ( Aldaz, A; Calvo, E; Escoriaza, J; Giráldez, J, 1999) |
| "We analyzed 26 patients with advanced gastric cancer in whom at least one of the tumor markers CEA, CA19-9 and CA125 was elevated before systemic chemotherapy with regard to the relationship between the change in serum tumor marker level and response assessment by imaging studies throughout the treatment course." | 1.30 | Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. ( Handa, T; Kai, S; Kazami, A; Koizumi, K; Maruyama, M; Takemoto, N; Yamao, T, 1999) |
| "Tegafur was fractionated from biological fluids by extraction with dichloromethane and analyzed by HPLC." | 1.30 | Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass sp ( Kitamura, R; Matsushima, E; Yoshida, K, 1997) |
| " The method was used to monitor the pharmacokinetic profile of 5-FUra and its two metabolites in patients with metastatic colorectal cancer." | 1.30 | Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study. ( Astre, C; Bressolle, F; Grosse, PY; Joulia, JM; Pinguet, F, 1997) |
| "Flank tumors measuring approximately 1." | 1.29 | Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy. ( Blackstock, AW; Branch, C; Kwock, L; Tepper, JE; Zeman, EM, 1996) |
| "Thirteen (23%) of 56 women had no residual tumor." | 1.29 | Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. ( Adler, DD; Cody, RL; Helvie, MA; Joynt, LK; Merajver, SD; Pierce, LJ, 1996) |
| "A total of 1216 patients with resected colon cancer, 1017 (84%) of whom had CEA monitoring." | 1.29 | An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. ( Fleming, TR; Haller, DG; Laurie, JA; Macdonald, JS; Moertel, CG; Tangen, C, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 33 (14.22) | 18.2507 |
| 2000's | 133 (57.33) | 29.6817 |
| 2010's | 61 (26.29) | 24.3611 |
| 2020's | 5 (2.16) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Awale, S | 1 |
| Li, F | 1 |
| Onozuka, H | 1 |
| Esumi, H | 1 |
| Tezuka, Y | 1 |
| Kadota, S | 1 |
| Ismail, MA | 1 |
| Youssef, MM | 1 |
| Arafa, RK | 1 |
| Al-Shihry, SS | 1 |
| El-Sayed, WM | 1 |
| Kaissis, G | 1 |
| Ziegelmayer, S | 1 |
| Lohöfer, F | 1 |
| Steiger, K | 1 |
| Algül, H | 1 |
| Muckenhuber, A | 1 |
| Yen, HY | 1 |
| Rummeny, E | 1 |
| Friess, H | 2 |
| Schmid, R | 1 |
| Weichert, W | 1 |
| Siveke, JT | 1 |
| Braren, R | 1 |
| Crimì, F | 1 |
| Capelli, G | 1 |
| Spolverato, G | 1 |
| Bao, QR | 1 |
| Florio, A | 1 |
| Milite Rossi, S | 1 |
| Cecchin, D | 1 |
| Albertoni, L | 1 |
| Campi, C | 1 |
| Pucciarelli, S | 1 |
| Stramare, R | 1 |
| Zhang, J | 1 |
| Winters, K | 1 |
| Kiser, K | 1 |
| Baboli, M | 1 |
| Kim, SG | 1 |
| Wang, C | 1 |
| Zhao, K | 1 |
| Hu, S | 2 |
| Huang, Y | 1 |
| Ma, L | 1 |
| Song, Y | 1 |
| Li, M | 1 |
| Golan, T | 1 |
| O'Kane, GM | 1 |
| Denroche, RE | 1 |
| Raitses-Gurevich, M | 1 |
| Grant, RC | 1 |
| Holter, S | 1 |
| Wang, Y | 1 |
| Zhang, A | 1 |
| Jang, GH | 1 |
| Stossel, C | 1 |
| Atias, D | 1 |
| Halperin, S | 1 |
| Berger, R | 1 |
| Glick, Y | 1 |
| Park, JP | 1 |
| Cuggia, A | 1 |
| Williamson, L | 1 |
| Wong, HL | 1 |
| Schaeffer, DF | 1 |
| Renouf, DJ | 1 |
| Borgida, A | 1 |
| Dodd, A | 1 |
| Wilson, JM | 1 |
| Fischer, SE | 1 |
| Notta, F | 1 |
| Knox, JJ | 1 |
| Zogopoulos, G | 1 |
| Gallinger, S | 1 |
| Shiraiwa, K | 1 |
| Suzuki, Y | 1 |
| Uchida, H | 1 |
| Iwashita, Y | 1 |
| Tanaka, R | 1 |
| Iwao, M | 1 |
| Tada, K | 1 |
| Hirashita, T | 1 |
| Masuda, T | 1 |
| Endo, Y | 1 |
| Inomata, M | 1 |
| Itoh, H | 1 |
| Yoon, YS | 1 |
| Kim, CW | 1 |
| Roh, SA | 1 |
| Cho, DH | 1 |
| Kim, TW | 1 |
| Kim, MB | 1 |
| Kim, JC | 1 |
| Baik, H | 1 |
| Lee, SM | 1 |
| Seo, SH | 1 |
| An, MS | 1 |
| Kim, KH | 1 |
| Bae, KB | 1 |
| Oh, MK | 1 |
| Hong, KH | 1 |
| Hermunen, K | 1 |
| Lantto, E | 1 |
| Poussa, T | 1 |
| Haglund, C | 1 |
| Österlund, P | 1 |
| Krzyzanski, W | 1 |
| Dunlavey, M | 1 |
| Odawara, S | 1 |
| Kitajima, K | 1 |
| Katsuura, T | 1 |
| Kurahashi, Y | 1 |
| Shinohara, H | 1 |
| Yamakado, K | 1 |
| Marchegiani, G | 1 |
| Todaro, V | 1 |
| Boninsegna, E | 1 |
| Negrelli, R | 1 |
| Sureka, B | 1 |
| Bonamini, D | 1 |
| Salvia, R | 1 |
| Manfredi, R | 1 |
| Pozzi Mucelli, R | 1 |
| Bassi, C | 1 |
| Dhersin, A | 1 |
| Atgé, B | 1 |
| Martinez, B | 1 |
| Titier, K | 1 |
| Rousset, M | 1 |
| Sidatt Cheikh El Moustaph, M | 1 |
| Verdun-Esquer, C | 1 |
| Molimard, M | 1 |
| Villa, A | 1 |
| Canal-Raffin, M | 1 |
| Granata, V | 1 |
| Fusco, R | 1 |
| Setola, SV | 1 |
| Palaia, R | 1 |
| Albino, V | 1 |
| Piccirillo, M | 1 |
| Grimm, R | 1 |
| Petrillo, A | 1 |
| Izzo, F | 1 |
| Neely, D | 1 |
| Ong, J | 1 |
| Patterson, J | 1 |
| Kirkpatrick, D | 1 |
| Skelly, R | 1 |
| Ganti, V | 1 |
| Walker, EA | 1 |
| Nagar, S | 1 |
| Heinzow, HS | 1 |
| Seifert, H | 1 |
| Tsepetonidis, S | 1 |
| Wolters, H | 1 |
| Kucharzik, T | 1 |
| Domschke, W | 1 |
| Domagk, D | 1 |
| Meister, T | 1 |
| Ji, M | 1 |
| Xu, B | 1 |
| Jiang, JT | 1 |
| Wu, J | 1 |
| Li, XD | 1 |
| Zhao, WQ | 1 |
| Zhang, HY | 1 |
| Zhou, WJ | 1 |
| Wu, CP | 1 |
| Huang, L | 1 |
| Cai, YJ | 1 |
| Lung, I | 1 |
| Leung, BC | 1 |
| Burd, A | 1 |
| Cunha-Junior, GF | 1 |
| De Marco, L | 1 |
| Bastos-Rodrigues, L | 1 |
| Bolina, MB | 1 |
| Martins, FL | 1 |
| Pianetti, GA | 1 |
| Cesar, IC | 1 |
| Coelho, LG | 1 |
| Bernhard, J | 1 |
| Dietrich, D | 1 |
| Glimelius, B | 2 |
| Bodoky, G | 1 |
| Scheithauer, W | 2 |
| Herrmann, R | 1 |
| Lee, JH | 1 |
| Jang, HS | 1 |
| Kim, JG | 1 |
| Lee, MA | 1 |
| Kim, DY | 1 |
| Kim, TH | 1 |
| Oh, JH | 1 |
| Park, SC | 1 |
| Kim, SY | 1 |
| Baek, JY | 1 |
| Park, HC | 1 |
| Kim, HC | 1 |
| Nam, TK | 1 |
| Chie, EK | 1 |
| Jung, JH | 1 |
| Oh, ST | 1 |
| Nöpel-Dünnebacke, S | 1 |
| Schulmann, K | 1 |
| Reinacher-Schick, A | 1 |
| Porschen, R | 1 |
| Schmiegel, W | 1 |
| Tannapfel, A | 1 |
| Graeven, U | 1 |
| Ryoo, I | 1 |
| Kim, JH | 1 |
| Choi, SH | 1 |
| Sohn, CH | 1 |
| Kim, SC | 1 |
| Champion, L | 1 |
| Lerebours, F | 1 |
| Alberini, JL | 1 |
| Fourme, E | 1 |
| Gontier, E | 2 |
| Bertrand, F | 1 |
| Wartski, M | 1 |
| Codacci-Pisanelli, G | 2 |
| Noordhuis, P | 4 |
| van der Wilt, CL | 4 |
| Peters, GJ | 6 |
| Paré, L | 1 |
| Salazar, J | 1 |
| del Rio, E | 1 |
| Baiget, M | 1 |
| Altés, A | 1 |
| Marcuello, E | 1 |
| Paez, D | 1 |
| Barnadas, A | 1 |
| Pisters, PW | 1 |
| Evans, DB | 1 |
| Woo, YA | 1 |
| Kim, GH | 1 |
| Jeong, EJ | 1 |
| Kim, CY | 1 |
| Lenhart, PD | 1 |
| Randleman, JB | 1 |
| Grossniklaus, HE | 1 |
| Stulting, RD | 1 |
| Tong, C | 1 |
| Shi, B | 1 |
| Xiao, X | 2 |
| Liao, H | 1 |
| Zheng, Y | 1 |
| Shen, G | 1 |
| Tang, D | 1 |
| Liu, X | 1 |
| Tausch, C | 1 |
| Konstantiniuk, P | 1 |
| Kugler, F | 1 |
| Reitsamer, R | 1 |
| Roka, S | 1 |
| Pöstlberger, S | 1 |
| Haid, A | 1 |
| Prasad, BB | 1 |
| Tiwari, K | 1 |
| Singh, M | 1 |
| Sharma, PS | 1 |
| Patel, AK | 1 |
| Srivastava, S | 1 |
| Le, QA | 1 |
| Hay, JW | 1 |
| Kovalova, L | 1 |
| McArdell, CS | 1 |
| Hollender, J | 1 |
| Zhu, Y | 1 |
| Warrick, JW | 1 |
| Haubert, K | 1 |
| Beebe, DJ | 1 |
| Yin, J | 1 |
| Tumeh, JW | 1 |
| Shenoy, PJ | 1 |
| Moore, SG | 1 |
| Kauh, J | 1 |
| Flowers, C | 1 |
| Marugami, N | 1 |
| Tanaka, T | 1 |
| Kitano, S | 1 |
| Hirohashi, S | 1 |
| Nishiofuku, H | 1 |
| Takahashi, A | 1 |
| Sakaguchi, H | 1 |
| Matsuoka, M | 1 |
| Otsuji, T | 1 |
| Takahama, J | 1 |
| Higashiura, W | 1 |
| Kichikawa, K | 1 |
| Chen, ML | 1 |
| Fang, CH | 1 |
| Liang, LS | 1 |
| Dai, LH | 1 |
| Wang, XK | 1 |
| Uehara, T | 1 |
| Yokoi, A | 1 |
| Aoshima, K | 1 |
| Tanaka, S | 1 |
| Kadowaki, T | 1 |
| Tanaka, M | 1 |
| Oda, Y | 1 |
| Kim, SH | 2 |
| Lee, JM | 1 |
| Park, HS | 1 |
| Eun, HW | 1 |
| Han, JK | 2 |
| Choi, BI | 2 |
| Capirci, C | 1 |
| Rubello, D | 1 |
| Pasini, F | 1 |
| Galeotti, F | 1 |
| Bianchini, E | 1 |
| Del Favero, G | 1 |
| Panzavolta, R | 1 |
| Crepaldi, G | 1 |
| Rampin, L | 1 |
| Facci, E | 1 |
| Gava, M | 1 |
| Banti, E | 1 |
| Marano, G | 1 |
| Mullot, JU | 1 |
| Karolak, S | 1 |
| Fontova, A | 1 |
| Huart, B | 1 |
| Levi, Y | 1 |
| Carli, D | 1 |
| Honorat, M | 1 |
| Cohen, S | 1 |
| Megherbi, M | 1 |
| Vignal, B | 1 |
| Dumontet, C | 1 |
| Payen, L | 1 |
| Guitton, J | 1 |
| Yuan, SQ | 1 |
| Zhou, ZW | 1 |
| Liang, YJ | 1 |
| Fu, LW | 1 |
| Chen, G | 1 |
| Keshari, RP | 1 |
| Zhang, LY | 1 |
| Iacconi, C | 1 |
| Giannelli, M | 1 |
| Marini, C | 1 |
| Cilotti, A | 1 |
| Moretti, M | 1 |
| Viacava, P | 1 |
| Picano, E | 1 |
| Michelotti, A | 1 |
| Caramella, D | 1 |
| Alanazi, FK | 1 |
| Yassin, AE | 1 |
| El-Badry, M | 1 |
| Mowafy, HA | 1 |
| Alsarra, IA | 1 |
| Booth, CM | 1 |
| Ohorodnyk, P | 1 |
| Eisenhauer, EA | 1 |
| Puglisi, F | 3 |
| Dose-Schwarz, J | 1 |
| Tiling, R | 1 |
| Avril-Sassen, S | 1 |
| Mahner, S | 1 |
| Lebeau, A | 1 |
| Weber, C | 1 |
| Schwaiger, M | 1 |
| Jänicke, F | 1 |
| Untch, M | 1 |
| Avril, N | 1 |
| Xie, P | 1 |
| Yue, JB | 1 |
| Zhao, HX | 1 |
| Sun, XD | 1 |
| Kong, L | 1 |
| Fu, Z | 1 |
| Yu, JM | 1 |
| Lee, JK | 1 |
| Coutant, C | 1 |
| Kim, YC | 1 |
| Qi, Y | 1 |
| Theodorescu, D | 1 |
| Symmans, WF | 3 |
| Baggerly, K | 1 |
| Rouzier, R | 2 |
| Pusztai, L | 3 |
| Matter-Walstra, KW | 1 |
| Dedes, KJ | 1 |
| Schwenkglenks, M | 1 |
| Brauchli, P | 1 |
| Szucs, TD | 1 |
| Pestalozzi, BC | 1 |
| Mochizuki, S | 1 |
| Yoshino, T | 1 |
| Kojima, T | 1 |
| Fuse, N | 1 |
| Ikematsu, H | 1 |
| Minashi, K | 1 |
| Yano, T | 1 |
| Tahara, M | 1 |
| Kaneko, K | 1 |
| Doi, T | 1 |
| Koike, K | 1 |
| Ohtsu, A | 1 |
| Montange, D | 1 |
| Bérard, M | 1 |
| Demarchi, M | 1 |
| Muret, P | 1 |
| Piédoux, S | 1 |
| Kantelip, JP | 1 |
| Royer, B | 1 |
| Kelly, P | 1 |
| Appleyard, V | 1 |
| Murray, K | 1 |
| Paulin, F | 1 |
| Lamont, D | 1 |
| Baker, L | 1 |
| Suttie, S | 1 |
| Exon, D | 1 |
| Thompson, A | 1 |
| Serve, KM | 1 |
| Darnell, JL | 1 |
| Takemoto, JK | 1 |
| Davies, NM | 1 |
| Black, ME | 1 |
| Arbea, L | 2 |
| Díaz-González, JA | 1 |
| Subtil, JC | 2 |
| Sola, J | 2 |
| Hernandez-Lizoain, JL | 2 |
| Martínez-Monge, R | 1 |
| Moreno, M | 1 |
| Aristu, J | 2 |
| Koiwai, K | 1 |
| Shikama, N | 1 |
| Sasaki, S | 1 |
| Shinoda, A | 1 |
| Kadoya, M | 1 |
| Aydoğan, S | 1 |
| Kuştimur, S | 1 |
| Kalkancı, A | 1 |
| Chen, J | 1 |
| Zhou, M | 1 |
| Chen, Y | 2 |
| Zuo, J | 1 |
| Liu, Y | 1 |
| Gao, H | 1 |
| Liu, W | 2 |
| Naoi, Y | 1 |
| Kishi, K | 1 |
| Tanei, T | 1 |
| Tsunashima, R | 1 |
| Tominaga, N | 1 |
| Baba, Y | 1 |
| Kim, SJ | 1 |
| Taguchi, T | 1 |
| Tamaki, Y | 1 |
| Noguchi, S | 1 |
| Tixier, F | 1 |
| Le Rest, CC | 1 |
| Hatt, M | 1 |
| Albarghach, N | 1 |
| Pradier, O | 1 |
| Metges, JP | 1 |
| Corcos, L | 1 |
| Visvikis, D | 1 |
| Tandon, M | 1 |
| Mishra, A | 1 |
| Agarwal, U | 1 |
| Saxena, S | 1 |
| Lambrecht, M | 1 |
| Vandecaveye, V | 1 |
| De Keyzer, F | 1 |
| Roels, S | 1 |
| Penninckx, F | 1 |
| Van Cutsem, E | 1 |
| Filip, C | 1 |
| Haustermans, K | 1 |
| Leibold, T | 1 |
| Akhurst, TJ | 1 |
| Chessin, DB | 1 |
| Yeung, HW | 1 |
| Macapinlac, H | 2 |
| Shia, J | 2 |
| Minsky, BD | 1 |
| Saltz, LB | 1 |
| Riedel, E | 1 |
| Mazumdar, M | 2 |
| Paty, PB | 1 |
| Weiser, MR | 1 |
| Wong, WD | 1 |
| Larson, SM | 2 |
| Guillem, JG | 1 |
| He, JH | 1 |
| Zhang, XY | 1 |
| Wu, FY | 1 |
| Liao, XL | 1 |
| Wang, W | 1 |
| Jiang, JW | 1 |
| Watanabe, T | 1 |
| Kobunai, T | 1 |
| Yamamoto, Y | 1 |
| Matsuda, K | 1 |
| Ishihara, S | 1 |
| Nozawa, K | 1 |
| Iinuma, H | 1 |
| Ikeuchi, H | 1 |
| Zhuo, LJ | 1 |
| Gao, MQ | 1 |
| Huang, AM | 1 |
| Pastor, C | 2 |
| Baixauli, J | 1 |
| Beorlegui, C | 1 |
| Garcia-Aguilar, J | 1 |
| Chen, Z | 1 |
| Smith, DD | 1 |
| Li, W | 1 |
| Madoff, RD | 1 |
| Cataldo, P | 1 |
| Marcet, J | 1 |
| Gollub, MJ | 1 |
| Gultekin, DH | 1 |
| Akin, O | 1 |
| Do, RK | 1 |
| Fuqua, JL | 1 |
| Gonen, M | 1 |
| Kuk, D | 1 |
| Weiser, M | 1 |
| Saltz, L | 1 |
| Schrag, D | 1 |
| Goodman, K | 1 |
| Paty, P | 1 |
| Guillem, J | 1 |
| Nash, GM | 1 |
| Temple, L | 1 |
| Schwartz, LH | 1 |
| Liberato, NL | 1 |
| Rognoni, C | 1 |
| Rubrichi, S | 1 |
| Quaglini, S | 1 |
| Marchetti, M | 1 |
| Gorlia, T | 1 |
| Licitra, L | 1 |
| Vermorken, JB | 1 |
| Della Vittoria Scarpati, G | 1 |
| Falcetta, F | 1 |
| Carlomagno, C | 1 |
| Ubezio, P | 1 |
| Marchini, S | 1 |
| De Stefano, A | 1 |
| Singh, VK | 1 |
| D'Incalci, M | 1 |
| De Placido, S | 1 |
| Pepe, S | 1 |
| Ferrand, FR | 1 |
| Guymar, S | 1 |
| Fagot, T | 1 |
| Ceccaldi, B | 1 |
| Malfuson, JV | 1 |
| de Revel, T | 1 |
| Büchel, B | 1 |
| Rhyn, P | 1 |
| Schürch, S | 1 |
| Bühr, C | 1 |
| Amstutz, U | 1 |
| Largiadèr, CR | 1 |
| Kim, DH | 1 |
| Im, SA | 1 |
| Han, SW | 1 |
| Goo, JM | 1 |
| Willmann, JK | 1 |
| Lee, ES | 1 |
| Eo, JS | 1 |
| Paeng, JC | 1 |
| Peer, CJ | 1 |
| McManus, TJ | 1 |
| Hurwitz, HI | 1 |
| Petros, WP | 1 |
| Mistrangelo, M | 1 |
| Pelosi, E | 1 |
| Bellò, M | 1 |
| Ricardi, U | 1 |
| Milanesi, E | 1 |
| Cassoni, P | 1 |
| Baccega, M | 1 |
| Filippini, C | 1 |
| Racca, P | 1 |
| Lesca, A | 1 |
| Munoz, FH | 1 |
| Fora, G | 1 |
| Skanjeti, A | 1 |
| Cravero, F | 1 |
| Morino, M | 1 |
| Yu, J | 1 |
| Gao, J | 1 |
| Lu, Z | 2 |
| Li, Y | 1 |
| Shen, L | 1 |
| Karp, G | 1 |
| Abu-Ghanem, S | 1 |
| Novack, V | 1 |
| Mermershtain, W | 1 |
| Ariad, S | 1 |
| Sion-Vardy, N | 1 |
| Livneh, E | 1 |
| Seki, H | 1 |
| Ozaki, T | 1 |
| Ooi, H | 1 |
| Byström, P | 1 |
| Berglund, Å | 1 |
| Nygren, P | 1 |
| Wernroth, L | 1 |
| Johansson, B | 1 |
| Larsson, A | 1 |
| Kim, G | 1 |
| Jung, EJ | 1 |
| Ryu, CG | 1 |
| Hwang, DY | 1 |
| Deenen, MJ | 1 |
| Rosing, H | 1 |
| Hillebrand, MJ | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Arienti, C | 1 |
| Tesei, A | 1 |
| Verdecchia, GM | 1 |
| Framarini, M | 1 |
| Virzì, S | 1 |
| Grassi, A | 1 |
| Scarpi, E | 1 |
| Turci, L | 1 |
| Silvestrini, R | 1 |
| Amadori, D | 1 |
| Zoli, W | 1 |
| Smid, K | 1 |
| Voorn, D | 1 |
| Pinedo, HM | 2 |
| Leśniewski-Kmak, K | 2 |
| Zieliński, KW | 1 |
| Szczylik, C | 1 |
| Manuskiatti, W | 1 |
| Fitzpatrick, RE | 1 |
| Iwashyna, TJ | 1 |
| Lamont, EB | 1 |
| Casale, F | 1 |
| Canaparo, R | 1 |
| Muntoni, E | 1 |
| Serpe, L | 1 |
| Zara, GP | 1 |
| Della Pepa, C | 1 |
| Berno, E | 1 |
| Costa, M | 1 |
| Eandi, M | 1 |
| Dittmann, H | 1 |
| Dohmen, BM | 1 |
| Kehlbach, R | 1 |
| Bartusek, G | 1 |
| Pritzkow, M | 1 |
| Sarbia, M | 1 |
| Bares, R | 1 |
| Misaki, T | 1 |
| Iwata, M | 1 |
| Iida, Y | 1 |
| Kasagi, K | 1 |
| Konishi, J | 1 |
| Heidemann, E | 1 |
| Stoeger, H | 1 |
| Souchon, R | 1 |
| Hirschmann, WD | 1 |
| Bodenstein, H | 1 |
| Oberhoff, C | 1 |
| Fischer, JT | 1 |
| Schulze, M | 1 |
| Clemens, M | 1 |
| Andreesen, R | 1 |
| Mahlke, M | 1 |
| König, M | 1 |
| Scharl, A | 1 |
| Fehnle, K | 1 |
| Kaufmann, M | 1 |
| Waters, JS | 1 |
| Tait, D | 1 |
| Cunningham, D | 1 |
| Padhani, AR | 1 |
| Hill, ME | 1 |
| Falk, S | 2 |
| Lofts, F | 1 |
| Norman, A | 1 |
| Oates, J | 1 |
| Hill, A | 1 |
| Chang, HM | 1 |
| Jung, KH | 1 |
| Kim, TY | 1 |
| Kim, WS | 1 |
| Yang, HK | 1 |
| Lee, KU | 1 |
| Choe, KJ | 1 |
| Heo, DS | 1 |
| Bang, YJ | 1 |
| Kim, NK | 1 |
| Aquino, A | 1 |
| Prete, SP | 1 |
| Balduzzi, A | 1 |
| Fossile, E | 1 |
| Formica, V | 1 |
| Torino, F | 1 |
| Bonmassar, L | 1 |
| Di Giacomo, A | 1 |
| Cappelletti, D | 1 |
| Cardillo, A | 1 |
| Graziani, G | 1 |
| Danesi, R | 1 |
| Di Paolo, A | 1 |
| Aschele, C | 2 |
| Debernardis, D | 1 |
| Bandelloni, R | 1 |
| Cascinu, S | 1 |
| Catalano, V | 1 |
| Giordani, P | 1 |
| Barni, S | 1 |
| Turci, D | 1 |
| Drudi, G | 1 |
| Lonardi, S | 1 |
| Gallo, L | 1 |
| Maley, F | 1 |
| Monfardini, S | 1 |
| Kitagawa, Y | 2 |
| Sano, K | 2 |
| Nishizawa, S | 2 |
| Nakamura, M | 2 |
| Ogasawara, T | 2 |
| Sadato, N | 2 |
| Yonekura, Y | 2 |
| Schneider, T | 1 |
| Osl, F | 1 |
| Friess, T | 1 |
| Stockinger, H | 2 |
| Scheuer, WV | 1 |
| Gross, E | 1 |
| Seck, K | 1 |
| Neubauer, S | 1 |
| Mayr, J | 1 |
| Hellebrand, H | 1 |
| Ratanaphan, A | 1 |
| Lutz, V | 1 |
| Kiechle, M | 1 |
| Yoshida, M | 1 |
| Hoshida, Y | 1 |
| Moriyama, M | 1 |
| Otsuka, M | 1 |
| Kato, N | 1 |
| Goto, T | 1 |
| Taniguchi, H | 1 |
| Shiratori, Y | 1 |
| Seki, N | 1 |
| Omata, M | 1 |
| Chesnay, E | 1 |
| Babin, E | 1 |
| Constans, JM | 1 |
| Agostini, D | 1 |
| Bequignon, A | 1 |
| Regeasse, A | 1 |
| Sobrio, F | 1 |
| Moreau, S | 1 |
| Lu, HJ | 1 |
| Guo, YL | 1 |
| Zhang, H | 1 |
| Ou, QY | 1 |
| Fujii, R | 1 |
| Seshimo, A | 1 |
| Kameoka, S | 1 |
| Kubota, T | 3 |
| Omura, K | 1 |
| Lin, Hs | 1 |
| D'Rosario, T | 1 |
| Micke, O | 1 |
| Bruns, F | 1 |
| Kurowski, R | 1 |
| Horst, E | 1 |
| deVries, AF | 1 |
| Hausler, JW | 1 |
| Willich, N | 1 |
| Schäfer, U | 1 |
| Van Rijnsoever, M | 1 |
| Elsaleh, H | 2 |
| Joseph, D | 2 |
| McCaul, K | 1 |
| Iacopetta, B | 2 |
| Chu, D | 1 |
| Gu, J | 1 |
| Paul Fawcett, J | 1 |
| Dong, Q | 1 |
| Belvedere, O | 1 |
| Di Loreto, C | 2 |
| Cataldi, P | 1 |
| Guglielmi, A | 1 |
| Sobrero, A | 1 |
| Mizutani, Y | 1 |
| Wada, H | 1 |
| Fukushima, M | 3 |
| Yoshida, O | 1 |
| Nakanishi, H | 1 |
| Li, YN | 1 |
| Miki, T | 1 |
| Emura, T | 1 |
| Murakami, Y | 1 |
| Nakagawa, F | 1 |
| Kitazato, K | 1 |
| Alauddin, MM | 1 |
| Shahinian, A | 1 |
| Park, R | 1 |
| Tohme, M | 1 |
| Fissekis, JD | 1 |
| Conti, PS | 1 |
| Mattison, LK | 1 |
| Ezzeldin, H | 1 |
| Carpenter, M | 1 |
| Modak, A | 1 |
| Johnson, MR | 2 |
| Diasio, RB | 3 |
| Gregory, BW | 1 |
| Baggerly, KA | 1 |
| Peng, B | 1 |
| Koomen, J | 1 |
| Kuerer, HM | 1 |
| Esteva, FJ | 1 |
| Wagner, P | 1 |
| Hortobagyi, GN | 2 |
| Laronga, C | 1 |
| Semmes, OJ | 1 |
| Wright, GL | 1 |
| Drake, RR | 1 |
| Vlahou, A | 1 |
| Miyazono, F | 1 |
| Metzger, R | 1 |
| Warnecke-Eberz, U | 1 |
| Baldus, SE | 1 |
| Brabender, J | 1 |
| Bollschweiler, E | 1 |
| Doerfler, W | 1 |
| Mueller, RP | 1 |
| Dienes, HP | 1 |
| Aikou, T | 1 |
| Hoelscher, AH | 1 |
| Schneider, PM | 1 |
| Shintani, Y | 1 |
| Ohta, M | 1 |
| Hirabayashi, H | 1 |
| Tanaka, H | 2 |
| Iuchi, K | 1 |
| Nakagawa, K | 1 |
| Maeda, H | 1 |
| Kido, T | 1 |
| Miyoshi, S | 1 |
| Matsuda, H | 1 |
| Zufía, L | 1 |
| Aldaz, A | 2 |
| Giráldez, J | 2 |
| Dimitrakopoulou-Strauss, A | 1 |
| Strauss, LG | 1 |
| Burger, C | 1 |
| Rühl, A | 1 |
| Irngartinger, G | 1 |
| Stremmel, W | 1 |
| Rudi, J | 1 |
| Mahnik, SN | 1 |
| Rizovski, B | 1 |
| Fuerhacker, M | 1 |
| Mader, RM | 1 |
| Swisher, SG | 1 |
| Maish, M | 1 |
| Erasmus, JJ | 1 |
| Correa, AM | 1 |
| Ajani, JA | 1 |
| Bresalier, R | 1 |
| Komaki, R | 1 |
| Munden, RF | 1 |
| Putnam, JB | 1 |
| Rice, D | 1 |
| Smythe, WR | 1 |
| Vaporciyan, AA | 1 |
| Walsh, GL | 1 |
| Wu, TT | 1 |
| Roth, JA | 1 |
| Holwerda, U | 2 |
| Van Laar, JA | 2 |
| Knecht, R | 1 |
| Peters, S | 1 |
| Hambek, M | 2 |
| Solbach, C | 1 |
| Baghi, M | 1 |
| Gstöttner, W | 1 |
| Min, J | 1 |
| Traynor, D | 1 |
| Stegner, AL | 1 |
| Zhang, L | 1 |
| Hanigan, MH | 1 |
| Alexander, H | 1 |
| Alexander, S | 1 |
| Smorenburg, CH | 1 |
| Van Groeningen, CJ | 1 |
| Toffoli, G | 1 |
| Cecchin, E | 1 |
| Sabatini, L | 1 |
| Barbieri, A | 1 |
| Tosi, M | 1 |
| Violante, FS | 1 |
| Chen, CC | 1 |
| Lee, RC | 1 |
| Lin, JK | 2 |
| Wang, LW | 1 |
| Yang, SH | 2 |
| Arnold, CN | 1 |
| Blum, HE | 1 |
| Andersson, J | 1 |
| Larsson, L | 1 |
| Klaar, S | 1 |
| Holmberg, L | 1 |
| Nilsson, J | 1 |
| Inganäs, M | 1 |
| Carlsson, G | 1 |
| Ohd, J | 1 |
| Rudenstam, CM | 1 |
| Gustavsson, B | 1 |
| Bergh, J | 4 |
| Li, KM | 1 |
| Rivory, LP | 1 |
| Clarke, SJ | 1 |
| Pickles, MD | 1 |
| Lowry, M | 1 |
| Manton, DJ | 1 |
| Gibbs, P | 1 |
| Turnbull, LW | 1 |
| Verma, S | 1 |
| Maraninchi, D | 1 |
| O'Shaughnessy, J | 1 |
| Jamieson, C | 1 |
| Jones, S | 1 |
| Martín, M | 1 |
| McKendrick, J | 1 |
| Miles, D | 1 |
| Twelves, C | 2 |
| Hornberger, J | 1 |
| Cao, XW | 1 |
| Fu, ZR | 1 |
| Ding, GS | 1 |
| Pohlen, U | 2 |
| Rieger, H | 1 |
| Binnenhei, M | 1 |
| Reszka, RC | 1 |
| Buhr, HJ | 2 |
| Berger, G | 2 |
| Guichard, SM | 2 |
| Mayer, I | 1 |
| Jodrell, DI | 2 |
| Farrell, PJ | 1 |
| Altinyollar, H | 1 |
| Dingil, G | 1 |
| Berberoglu, U | 1 |
| Akhurst, T | 1 |
| Kates, TJ | 1 |
| Yeung, H | 1 |
| Riedel, ER | 1 |
| Burt, BM | 1 |
| Blumgart, L | 1 |
| Jarnagin, W | 1 |
| Fong, Y | 1 |
| Macpherson, JS | 1 |
| Jacobsson, H | 1 |
| Wilczek, B | 1 |
| von Schoultz, E | 1 |
| Eriksson, E | 1 |
| Larsson, SA | 1 |
| Déporte, R | 1 |
| Amiand, M | 1 |
| Moreau, A | 1 |
| Charbonnel, C | 1 |
| Campion, L | 1 |
| Cassidy, J | 1 |
| Douillard, JY | 1 |
| McKendrick, JJ | 1 |
| Bustová, I | 1 |
| Johnston, PG | 1 |
| Jelic, S | 1 |
| Fountzilas, G | 1 |
| Coxon, F | 1 |
| Díaz-Rubio, E | 1 |
| Maughan, TS | 2 |
| Malzyner, A | 1 |
| Bertetto, O | 1 |
| Beham, A | 1 |
| Figer, A | 1 |
| Dufour, P | 1 |
| Patel, KK | 1 |
| Cowell, W | 1 |
| Garrison, LP | 1 |
| Sakurai, Y | 1 |
| Sakamoto, K | 1 |
| Sugimoto, Y | 1 |
| Yoshida, I | 1 |
| Masui, T | 1 |
| Tonomura, S | 1 |
| Inaba, K | 1 |
| Shoji, M | 1 |
| Nakamura, Y | 1 |
| Uyama, I | 1 |
| Komori, Y | 1 |
| Ochiai, M | 1 |
| Matsuura, S | 1 |
| Oka, T | 1 |
| Green, LJ | 1 |
| Marder, P | 1 |
| Ray, C | 1 |
| Cook, CA | 1 |
| Jaken, S | 1 |
| Musib, LC | 1 |
| Herbst, RS | 1 |
| Carducci, M | 1 |
| Britten, CD | 1 |
| Basche, M | 1 |
| Eckhardt, SG | 1 |
| Thornton, D | 1 |
| Fagnoni, P | 1 |
| Limat, S | 1 |
| Chaigneau, L | 1 |
| Guardiola, E | 1 |
| Briaud, S | 1 |
| Schmitt, B | 1 |
| Merrouche, Y | 1 |
| Pivot, X | 1 |
| Woronoff-Lemsi, MC | 1 |
| Pavel, I | 1 |
| Cota, S | 1 |
| Cînta-Pînzaru, S | 1 |
| Kiefer, W | 1 |
| Hess, KR | 1 |
| Anderson, K | 1 |
| Valero, V | 1 |
| Ibrahim, N | 1 |
| Mejia, JA | 1 |
| Booser, D | 1 |
| Theriault, RL | 1 |
| Buzdar, AU | 2 |
| Dempsey, PJ | 1 |
| Sneige, N | 1 |
| Ross, JS | 1 |
| Vidaurre, T | 1 |
| Gómez, HL | 1 |
| Mehta, JS | 1 |
| Maurino, V | 1 |
| Patel, H | 1 |
| Kirwin, J | 1 |
| Murdoch, IE | 1 |
| de Geus-Oei, LF | 1 |
| Ruers, TJ | 1 |
| Punt, CJ | 1 |
| Leer, JW | 1 |
| Corstens, FH | 1 |
| Oyen, WJ | 1 |
| Schrohl, AS | 1 |
| Meijer-van Gelder, ME | 1 |
| Holten-Andersen, MN | 1 |
| Christensen, IJ | 1 |
| Look, MP | 1 |
| Mouridsen, HT | 1 |
| Brünner, N | 1 |
| Foekens, JA | 1 |
| Demiray, M | 1 |
| Ulukaya, EE | 1 |
| Arslan, M | 1 |
| Gokgoz, S | 1 |
| Saraydaroglu, O | 1 |
| Ercan, I | 1 |
| Evrensel, T | 1 |
| Manavoglu, O | 1 |
| Khanfir, A | 1 |
| Frikha, M | 1 |
| Kallel, F | 1 |
| Meziou, M | 1 |
| Trabelsi, K | 1 |
| Boudawara, T | 1 |
| Mnif, J | 1 |
| Daoud, J | 1 |
| Temmink, OH | 1 |
| Prins, HJ | 1 |
| van Gelderop, E | 1 |
| Yoshimasu, T | 1 |
| Oura, S | 1 |
| Hirai, I | 1 |
| Tamaki, T | 1 |
| Kokawa, Y | 1 |
| Hata, K | 1 |
| Ohta, F | 1 |
| Nakamura, R | 1 |
| Kawago, M | 1 |
| Tanino, H | 1 |
| Okamura, Y | 1 |
| Furukawa, T | 2 |
| Glynne-Jones, R | 1 |
| Meadows, HM | 1 |
| Sebag-Montefiore, D | 1 |
| Zuo, X | 1 |
| Yang, X | 1 |
| Wang, K | 1 |
| Tan, W | 1 |
| Wen, J | 1 |
| Shang, D | 1 |
| Ito, N | 1 |
| Kamoto, T | 1 |
| Ogawa, O | 1 |
| Suttie, SA | 1 |
| Park, KG | 1 |
| Smith, TA | 1 |
| Bonnefoi, H | 1 |
| Potti, A | 1 |
| Delorenzi, M | 1 |
| Mauriac, L | 1 |
| Campone, M | 1 |
| Tubiana-Hulin, M | 1 |
| Petit, T | 1 |
| Rouanet, P | 1 |
| Jassem, J | 1 |
| Blot, E | 1 |
| Becette, V | 1 |
| Farmer, P | 1 |
| André, S | 1 |
| Acharya, CR | 1 |
| Mukherjee, S | 1 |
| Cameron, D | 1 |
| Nevins, JR | 1 |
| Iggo, RD | 1 |
| Hayashi, Y | 1 |
| Akiyama, J | 1 |
| Watanabe, M | 1 |
| Nozaki, Y | 1 |
| Iwashita, R | 1 |
| Nagaoki, Y | 1 |
| Sakurai, T | 1 |
| Oshima, T | 1 |
| Nagata, N | 1 |
| Yago, Y | 1 |
| Sako, A | 1 |
| Kobayakawa, M | 1 |
| Tamegai, Y | 1 |
| Masaki, N | 1 |
| Uemura, N | 1 |
| Umeda, N | 1 |
| Bleiweiss, IJ | 1 |
| Raptis, G | 1 |
| Lin, D | 1 |
| Glastonbury, CM | 1 |
| Rafaelian, O | 1 |
| Eisele, DW | 1 |
| Wang, SJ | 1 |
| Morikawa, S | 1 |
| Inubushi, T | 1 |
| Morita, M | 1 |
| Murakami, K | 1 |
| Masuda, C | 1 |
| Maki, J | 1 |
| Tooyama, I | 1 |
| Sugae, S | 1 |
| Suzuki, A | 1 |
| Takahashi, N | 1 |
| Minamimoto, R | 1 |
| Cheng, C | 1 |
| Theeraladanon, C | 1 |
| Endo, I | 1 |
| Togo, S | 1 |
| Inoue, T | 1 |
| Shimada, H | 2 |
| Wang, GH | 1 |
| Wang, J | 1 |
| Qi, W | 1 |
| Sun, LX | 1 |
| Cardellino, GG | 1 |
| Crivellari, D | 1 |
| Magri, MD | 1 |
| Minisini, AM | 1 |
| Mansutti, M | 1 |
| Andreetta, C | 1 |
| Russo, S | 1 |
| Lombardi, D | 1 |
| Perin, T | 1 |
| Damante, G | 1 |
| Veronesi, A | 1 |
| Showalter, SL | 1 |
| Showalter, TN | 1 |
| Witkiewicz, A | 1 |
| Havens, R | 1 |
| Kennedy, EP | 1 |
| Hucl, T | 1 |
| Kern, SE | 1 |
| Yeo, CJ | 1 |
| Brody, JR | 1 |
| Guo, M | 1 |
| Li, Q | 1 |
| Cai, Q | 1 |
| Yao, S | 1 |
| Grimes, CA | 1 |
| Austin, JR | 1 |
| Wong, FC | 1 |
| Kim, EE | 1 |
| Morgan, RJ | 1 |
| Speyer, J | 1 |
| Doroshow, JH | 1 |
| Margolin, K | 1 |
| Raschko, J | 1 |
| Sorich, J | 1 |
| Akman, S | 1 |
| Leong, L | 1 |
| Somlo, G | 1 |
| Vasilev, S | 1 |
| Moertel, CG | 1 |
| Fleming, TR | 1 |
| Macdonald, JS | 1 |
| Haller, DG | 1 |
| Laurie, JA | 1 |
| Tangen, C | 1 |
| Zhang, R | 1 |
| Smith, RD | 1 |
| Hall, J | 1 |
| Gurney, H | 1 |
| Harnett, PR | 1 |
| Helvie, MA | 1 |
| Joynt, LK | 1 |
| Cody, RL | 1 |
| Pierce, LJ | 1 |
| Adler, DD | 1 |
| Merajver, SD | 1 |
| Williamson, PR | 1 |
| Hellinger, MD | 1 |
| Larach, SW | 1 |
| Ferrara, A | 1 |
| Colucci, G | 1 |
| Komissarov, A | 1 |
| Kok, M | 1 |
| Van Groeningen, V | 1 |
| Yamada, Y | 1 |
| Yamada, T | 1 |
| Asanuma, F | 1 |
| Suzuki, T | 2 |
| Kawamura, E | 1 |
| Coe, RA | 1 |
| Earl, RA | 1 |
| Johnson, TC | 1 |
| Lee, JW | 1 |
| Messori, A | 1 |
| Becagli, P | 1 |
| Trippoli, S | 1 |
| Tendi, E | 1 |
| Blackstock, AW | 1 |
| Kwock, L | 1 |
| Branch, C | 1 |
| Zeman, EM | 1 |
| Tepper, JE | 1 |
| Matsushima, E | 1 |
| Yoshida, K | 2 |
| Kitamura, R | 1 |
| Joulia, JM | 1 |
| Pinguet, F | 1 |
| Grosse, PY | 1 |
| Astre, C | 1 |
| Bressolle, F | 1 |
| Gamelin, E | 2 |
| Boisdron-Celle, M | 2 |
| Turcant, A | 2 |
| Larra, F | 2 |
| Allain, P | 2 |
| Robert, J | 2 |
| Yan, J | 1 |
| Shao, L | 1 |
| Albin, N | 1 |
| Dees, EC | 1 |
| Shulman, LN | 1 |
| Souba, WW | 1 |
| Smith, BL | 1 |
| Maini, CL | 1 |
| Tofani, A | 1 |
| Sciuto, R | 1 |
| Semprebene, A | 1 |
| Cavaliere, R | 1 |
| Mottolese, M | 1 |
| Benevolo, M | 1 |
| Ferranti, F | 1 |
| Grandinetti, ML | 1 |
| Vici, P | 1 |
| Lopez, M | 1 |
| Botti, C | 1 |
| Jung, M | 1 |
| Päuser, S | 1 |
| Reszka, R | 1 |
| Foley, KP | 1 |
| McArthur, GA | 1 |
| Quéva, C | 1 |
| Hurlin, PJ | 1 |
| Soriano, P | 1 |
| Eisenman, RN | 1 |
| Amer, MM | 1 |
| Hassan, SS | 1 |
| Abd El-Fatah, SA | 1 |
| El-Kosasy, AM | 1 |
| Leccia, JR | 1 |
| Milano, G | 1 |
| Formento, P | 1 |
| Francoual, M | 1 |
| Formento, JL | 1 |
| Pierrefite, V | 1 |
| Bouil, AL | 1 |
| Delva, R | 1 |
| Cailleux, A | 1 |
| Krikorian, A | 1 |
| Brienza, S | 1 |
| Cvitkovic, E | 1 |
| Hoffman, RM | 1 |
| Zuccaro, G | 1 |
| Rice, TW | 1 |
| Goldblum, J | 1 |
| Medendorp, SV | 1 |
| Becker, M | 1 |
| Pimentel, R | 1 |
| Gitlin, L | 1 |
| Adelstein, DJ | 1 |
| Shamseddine, A | 2 |
| Khalil, A | 2 |
| Seoud, M | 2 |
| Kahwaji, S | 2 |
| Taher, A | 1 |
| Bizri, AR | 1 |
| Medawar, W | 2 |
| Ibrahim, K | 1 |
| Habbal, Z | 1 |
| Maeda, T | 1 |
| Sumi, S | 1 |
| Hayashi, K | 1 |
| Kidouchi, K | 1 |
| Owaki, T | 1 |
| Togari, H | 1 |
| Fujimoto, S | 1 |
| Wada, Y | 1 |
| Escoriaza, J | 1 |
| Calvo, E | 1 |
| Yamao, T | 1 |
| Kai, S | 1 |
| Kazami, A | 1 |
| Koizumi, K | 1 |
| Handa, T | 1 |
| Takemoto, N | 1 |
| Maruyama, M | 1 |
| Levy-Piedbois, C | 1 |
| Durand-Zaleski, I | 1 |
| Juhel, H | 1 |
| Schmitt, C | 1 |
| Bellanger, A | 1 |
| Piedbois, P | 1 |
| Ochiai, T | 1 |
| Nakajima, K | 1 |
| Matsubara, H | 1 |
| Arima, M | 1 |
| Hori, S | 1 |
| Hayashi, H | 1 |
| Takeda, A | 1 |
| Yanagawa, T | 1 |
| Sen, K | 1 |
| Robbins, P | 1 |
| Powell, B | 1 |
| Grieu, F | 1 |
| Menso, L | 1 |
| Vlastos, G | 1 |
| Fornage, BD | 1 |
| Mirza, NQ | 1 |
| Bedi, D | 1 |
| Lenert, JT | 1 |
| Winchester, DJ | 1 |
| Tolley, SM | 1 |
| Ames, FC | 1 |
| Ross, MI | 1 |
| Feig, BW | 1 |
| Hunt, KK | 1 |
| Singletary, SE | 1 |
| Waddell, BE | 1 |
| Lee, RJ | 1 |
| Rodriguez-Bigas, MA | 1 |
| Weber, TK | 1 |
| Petrelli, NJ | 1 |
| Iqbal, S | 1 |
| Lenz, HJ | 1 |
| Micoli, G | 1 |
| Turci, R | 1 |
| Arpellini, M | 1 |
| Minoia, C | 1 |
| Toraño, JS | 1 |
| Vermes, A | 1 |
| Guchelaar, HJ | 1 |
| Hanke, B | 1 |
| Riedel, C | 1 |
| Lampert, S | 1 |
| Happich, K | 1 |
| Martus, P | 1 |
| Parsch, H | 1 |
| Himmler, B | 1 |
| Hohenberger, W | 1 |
| Hahn, EG | 1 |
| Wein, A | 1 |
| Wang, WS | 1 |
| Lin, TC | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Fan, FS | 1 |
| Yen, CC | 1 |
| Chen, WS | 1 |
| Jiang, JK | 1 |
| Wang, HS | 1 |
| Chen, PM | 1 |
| Olsen, BA | 1 |
| Procházková, A | 1 |
| Liu, S | 1 |
| Aebi, S | 1 |
| Thormann, W | 1 |
| Slater, MS | 1 |
| Holland, J | 1 |
| Faigel, DO | 1 |
| Sheppard, BC | 1 |
| Deveney, CW | 1 |
| Nakamura, H | 1 |
| Sekiguchi, H | 1 |
| Akiyama, S | 1 |
| Hamada, H | 1 |
| Fujiwara, M | 1 |
| Kasai, Y | 1 |
| Ito, K | 1 |
| Nakao, A | 1 |
| Hashimoto, Y | 1 |
| Ueda, K | 1 |
| Minami, K | 1 |
| Watatani, M | 1 |
| Hernberg, M | 1 |
| Virkkunen, P | 1 |
| Maasilta, P | 1 |
| Keyriläinen, J | 1 |
| Blomqvist, C | 1 |
| Wiklund, T | 1 |
| Ryu, JS | 1 |
| Choi, NC | 1 |
| Fischman, AJ | 1 |
| Lynch, TJ | 1 |
| Mathisen, DJ | 1 |
| Sundararajan, V | 1 |
| Mitra, N | 1 |
| Jacobson, JS | 1 |
| Grann, VR | 1 |
| Heitjan, DF | 1 |
| Neugut, AI | 1 |
| Kleeberg, UR | 1 |
| Tonkin, K | 1 |
| Bates, M | 1 |
| Lieu, D | 1 |
| Arundell, E | 1 |
| Williamson, T | 1 |
| Zagari, M | 1 |
| Liem, LK | 1 |
| Choong, LH | 1 |
| Woo, KT | 1 |
| Garg, MB | 1 |
| Sevester, JC | 1 |
| Sakoff, JA | 1 |
| Ackland, SP | 1 |
| Ebina, T | 1 |
| Murata, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy[NCT05298722] | 45 participants (Anticipated) | Interventional | 2022-12-12 | Recruiting | |||
| The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair[NCT03219580] | Phase 3 | 50 participants (Anticipated) | Interventional | 2017-05-20 | Enrolling by invitation | ||
| Use of PET/MR Radiomics to Evaluate the Clinical Phenotypes, Response Status of Neoadjuvant Chemotherapy and Long-term Prognosis of Breast Cancer: a Preliminary Study[NCT05466760] | 120 participants (Anticipated) | Observational [Patient Registry] | 2018-07-06 | Recruiting | |||
| Timing of Rectal Cancer Response to Chemoradiation[NCT00335816] | Phase 2 | 248 participants (Anticipated) | Interventional | 2008-08-31 | Active, not recruiting | ||
| Timing To Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy For Rectal Cancer: A Multicenter Randomized Controlled Trial - Biomarkers SubStudy[NCT03962088] | 200 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
| Effect of Pulse Width of a 595-nm Flashlamp-pumped Pulsed-dye Laser on the Treatment Response of Keloidal and Hypertrophic Sternotomy Scars[NCT00142441] | 19 participants | Interventional | 2003-06-30 | Completed | |||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Could Positon Emission Tomography With Radiolabelled 3'-Deoxy-3'-(18)F-Fluoro-L-Thymidine be a Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patients ?[NCT02069418] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-02-28 | Active, not recruiting | ||
| MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS[NCT00002544] | Phase 3 | 300 participants (Anticipated) | Interventional | 1993-05-31 | Completed | ||
| Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333] | Phase 1 | 9 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| First Prospective Intergroup Translational Research Trial Assessing the Potential Predictive Value of p53 Using a Functional Assay in Yeast in Patients With Locally Advanced/Inflammatory or Large Operable Breast Cancer Prospectively Randomised to a Taxane[NCT00017095] | Phase 3 | 1,856 participants (Actual) | Interventional | 2001-03-31 | Completed | ||
| Tc-99m Sestamibi SPECT/CT for Prediction of the Response of Locally Advanced Breast Malignancy to Neoadjuvant Chemotherapy[NCT00804544] | 4 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to 4 patients have been enrolled into the pilot study. No complications reported. Another clinical trial has been designed.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
10 reviews available for fluorouracil and Sensitivity and Specificity
| Article | Year |
|---|---|
Small intestinal adenocarcinoma: rarely considered, often missed?
Topics: Adenocarcinoma; Aged; Capsule Endoscopy; Celiac Disease; Chemotherapy, Adjuvant; Cystic Fibrosis; Do | 2013 |
A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
5-fluorouracil and dihydropyrimidine dehydrogenase.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasms | 2003 |
Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2003 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplat | 2004 |
Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2004 |
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltran | 2004 |
[Colon cancer: molecular markers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; | 2005 |
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fluorouracil; | 2008 |
Determinants of prognosis and response to therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2001 |
44 trials available for fluorouracil and Sensitivity and Specificity
| Article | Year |
|---|---|
Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Ca | 2018 |
Diffusion kurtosis imaging and conventional diffusion weighted imaging to assess electrochemotherapy response in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidi | 2019 |
Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; China; Cisplatin; DN | 2013 |
Clinical benefit response in pancreatic cancer trials revisited.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Causality; Comorbidity; Deoxycy | 2014 |
Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10-01 and 11-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2014 |
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarke | 2014 |
18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2015 |
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 2010 |
Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2011 |
Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: preliminary results of a prospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Early Detection of Cancer; Femal | 2012 |
Localization of PKCη in cell membranes as a predictor for breast cancer response to treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Membrane; | 2012 |
Evaluation of predictive markers for patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; C- | 2012 |
Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments.
Topics: Adrenal Cortex Hormones; Adult; Aged; Biopsy, Needle; Cicatrix, Hypertrophic; Drug Therapy, Combinat | 2002 |
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast | 2002 |
A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle | 2002 |
Irinotecan in 5-fluorouracil-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administrati | 2002 |
FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combine | 2003 |
Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 2003 |
Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2003 |
Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; CA-19-9 Antige | 2003 |
Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Femal | 2004 |
Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survi | 2004 |
How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2005 |
Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
Capecitabine plus docetaxel combination therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combine | 2005 |
Different methods for the detection of small changes in uptake between single-photon emission computed tomography (SPECT) examinations: 99mTc-sestamibi in chemotherapy for breast tumours.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea | 2006 |
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2006 |
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Combined | 2007 |
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2007 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; CA-125 Antigen; Drug Therapy, Combination; Female; F | 1995 |
Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Sensitivity and Sp | 1996 |
Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benef | 1996 |
Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; C | 1997 |
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1997 |
The relation between erythropoietin, hematocrit and hemoglobin in breast cancer patients on non-nephrotoxic chemotherapy.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, | 1998 |
The relationship between serum levels of erythropoietin (EPO) and insulin-like growth factor-1 (ILGF-1) and hematocrit (HCT) in breast cancer patients receiving non-nephrotoxic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1998 |
Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2000 |
Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2000 |
The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasm | 2000 |
Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Admi | 2002 |
FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2002 |
Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cost-Benefi | 1996 |
178 other studies available for fluorouracil and Sensitivity and Specificity
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Necrosis; Nutriti | 2008 |
Synthesis and antiproliferative activity of monocationic arylthiophene derivatives.
Topics: Antineoplastic Agents; Antioxidants; Benzamidines; Cell Death; Cell Line, Tumor; Cell Proliferation; | 2017 |
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; | 2019 |
MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Female; Fluoroura | 2020 |
Assessment of tumor treatment response using active contrast encoding (ACE)-MRI: Comparison with conventional DCE-MRI.
Topics: Animals; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Contrast Media; Fluorouracil; Gadolin | 2020 |
A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2020 |
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplat | 2021 |
Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chroma | 2021 |
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2017 |
Prognostic value of positron emission tomography/computed tomography for adjuvant chemotherapy of colon cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coh | 2018 |
Evaluation of performance of distributed delay model for chemotherapy-induced myelosuppression.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Proliferation; Fluorouracil; Humans; Leukocyte Cou | 2018 |
Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female | 2018 |
Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Comb | 2018 |
Biomonitoring of occupational exposure to 5-FU by assaying α-fluoro-β-alanine in urine with a highly sensitive UHPLC-MS/MS method.
Topics: beta-Alanine; Chromatography, High Pressure Liquid; Environmental Monitoring; Fluorouracil; Humans; | 2018 |
Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine.
Topics: Animals; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Drug Stability; Fluorouracil; | 2013 |
Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblasts in vitro.
Topics: Analysis of Variance; Apoptosis; Blotting, Western; Cell Cycle; Cell Death; Cell Proliferation; Cell | 2013 |
(13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes; Dihy | 2013 |
Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm(2) to Predict Response to Induction Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2015 |
Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Flu | 2008 |
Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Colorectal | 2008 |
Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 2008 |
Simultaneous determination of doxifluridine and 5-fluorouracil in monkey serum by high performance liquid chromatography with tandem mass spectrometry.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid | 2008 |
Confocal microscopic diagnosis of epithelial downgrowth.
Topics: Adolescent; Adult; Aged; Cell Nucleus; Corneal Diseases; Epithelium, Corneal; Eye Injuries, Penetrat | 2008 |
An Annexin V-based biosensor for quantitatively detecting early apoptotic cells.
Topics: Adsorption; Annexin A5; Antineoplastic Agents; Apoptosis; Biosensing Techniques; Electrochemistry; E | 2009 |
Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Cyclophospha | 2008 |
Ultratrace analysis of uracil and 5-fluorouracil by molecularly imprinted polymer brushes grafted to silylated solid-phase microextraction fiber in combination with complementary molecularly imprinted polymer-based sensor.
Topics: Benzenesulfonates; Binding Sites; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; | 2009 |
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysi | 2009 |
Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry.
Topics: Adsorption; Chromatography, Liquid; Cytostatic Agents; Deoxycytidine; Drug Residues; Floxuridine; Fl | 2009 |
Infection on a chip: a microscale platform for simple and sensitive cell-based virus assays.
Topics: Animals; Antiviral Agents; Cell Culture Techniques; Cell Line; Cricetinae; Dose-Response Relationshi | 2009 |
A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; | 2009 |
Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasm | 2009 |
Quantitative phosphorus metabolomics using nanoflow liquid chromatography-tandem mass spectrometry and culture-derived comprehensive global internal standards.
Topics: Cell Line, Tumor; Chromatography, Liquid; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Metabolo | 2009 |
Accuracy of MRI for predicting the circumferential resection margin, mesorectal fascia invasion, and tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fascia; Female; Fluorouracil; | 2009 |
The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorodeoxyglucose F18; Flu | 2009 |
Development and validation of a sensitive and selective method using GC/MS-MS for quantification of 5-fluorouracil in hospital wastewater.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Gas Chromatography-Mass Spectrometry; Hospitals; Mode | 2009 |
Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS.
Topics: Cell Line; Cell Line, Tumor; Chromatography, Liquid; Deoxyuracil Nucleotides; Drug Stability; Floxur | 2009 |
[Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassett | 2009 |
The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: a preliminary study.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide | 2010 |
Validated high-performance liquid chromatographic technique for determination of 5-fluorouracil: applications to stability studies and simulated colonic media.
Topics: Animals; Cecum; Chromatography, High Pressure Liquid; Colon; Drug Stability; Fluorouracil; Gastroint | 2009 |
Call for clarity in the reporting of benefit associated with anticancer therapies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Editorial Policies; Fluorouracil; Ge | 2009 |
What does similarity mean in clinical trials?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Pha | 2009 |
Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; | 2010 |
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Breast Neo | 2010 |
Trastuzumab beyond progression: a cost-utility analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma.
Topics: Area Under Curve; Capecitabine; Chromatography, Liquid; Deoxycytidine; Drug Stability; Fluorouracil; | 2010 |
Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Lin | 2010 |
Validation of an isocratic HPLC method to detect 2-fluoro-beta-alanine for the analysis of dihydropyrimidine dehydrogenase activity.
Topics: beta-Alanine; Cell Line, Tumor; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; | 2010 |
Patterns of response after preoperative intensity-modulated radiation therapy and capecitabine/oxaliplatin in rectal cancer: is there still a place for ecoendoscopic ultrasound?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deox | 2011 |
Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Squa | 2010 |
[Comparison of glucan and galactomannan tests with real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model].
Topics: Animals; Antigens, Fungal; Aspergillus fumigatus; beta-Glucans; Bronchoalveolar Lavage Fluid; Diseas | 2010 |
Determination of eniluracil and 5-fluorouracil in human plasma by LC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Enzyme Inhibitors; Fluorouracil; Humans; Mass Spectrometry; Re | 2010 |
Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2010 |
Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2011 |
Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Com | 2011 |
Sentinel lymph node biopsy using dye alone method is reliable and accurate even after neo-adjuvant chemotherapy in locally advanced breast cancer--a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neopl | 2011 |
Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Diffus | 2012 |
Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fema | 2011 |
[Knock-down of apollon gene by antisense oligodeoxynucleotide inhibits the proliferation of Lovo cells and enhances chemo-sensitivity].
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colon | 2011 |
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2011 |
[Improved sensitivity of gastric carcinoma cells to fluorouracil-related drugs by transfection of thymidine phosphorylase gene].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Floxuridine; Fluorou | 2011 |
Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colonoscopy; Endosonography; | 2011 |
Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cost-Benefit An | 2012 |
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine | 2012 |
Effectiveness and safe use of modified FOLFOX-6 for metastatic gastric cancer with signet ring cell components complicated by disseminated intravascular coagulation and diffuse bone marrow carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma; Carcinoma, Signet | 2012 |
LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Chromatography, Liquid; Colorectal Neoplasms; Drug Monitoring | 2013 |
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
Role of positron emission tomography-computed tomography in the management of anal cancer.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, | 2012 |
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area | 2012 |
Dual-phase CT angiography through the port-catheter system for hepatic arterial infusion chemotherapy using multislice CT: assessment of system dysfunction and impact on predicting clinical problems.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatoc | 2012 |
Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2013 |
Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
Topics: Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Fluorouracil; Hum | 2013 |
Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colonic Neoplasms; D | 2013 |
High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil | 2002 |
Quantitative assessment of the clavicle radiostructure as a tool for estimation of the osteopathic effect of breast cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Breas | 2002 |
Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2002 |
Simultaneous HPLC determination of 5-fluorouracil and its metabolites in plasma of cancer patients.
Topics: Antimetabolites, Antineoplastic; Calibration; Chromatography, High Pressure Liquid; Fluorouracil; Hu | 2002 |
Early changes in [18F]FLT uptake after chemotherapy: an experimental study.
Topics: Antineoplastic Agents; Artifacts; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Deoxycytidine; | 2002 |
Chemo-radionuclide therapy for thyroid cancer: initial experimental study with cultured cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Cell Survival; Cisplatin; Dose | 2002 |
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne | 2002 |
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2002 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, N | 2002 |
High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.
Topics: Adult; Alleles; Amino Acid Substitution; Antineoplastic Agents; Biotransformation; Capecitabine; Chr | 2003 |
Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells.
Topics: Carcinoma, Hepatocellular; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; F | 2002 |
Rapid determination of 5-fluorouracil in plasma using capillary electrophoresis.
Topics: Animals; Chromatography, High Pressure Liquid; Electrophoresis, Capillary; Fluorouracil; Rabbits; Re | 2003 |
Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Cell Division; Co | 2003 |
Pretreatment growth environments alter the sensitivity of tumor cells to cytotoxic agents.
Topics: Agar; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antioxidants; Bleomycin; Carcinom | 2003 |
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; CpG Islands; DNA Methyl | 2003 |
Sensitive liquid chromatographic assay for the simultaneous determination of 5-fluorouracil and its prodrug, tegafur, in beagle dog plasma.
Topics: Animals; Antimetabolites, Antineoplastic; Calibration; Chromatography, High Pressure Liquid; Dogs; F | 2003 |
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle Proteins; Colorectal Neoplasms; DNA-Binding Pro | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
Synthesis of 2'-deoxy-2'-[18F]fluoro-5-bromo-1-beta-D-arabinofuranosyluracil ([18F]-FBAU) and 2'-deoxy-2'-[18F]fluoro-5-chloro-1-beta-D-arabinofuranosyl-uracil ([18F]-FCAU), and their biological evaluation as markers for gene expression.
Topics: Animals; Arabinofuranosyluracil; Biomarkers, Tumor; Bromouracil; Colonic Neoplasms; Fluorouracil; Ge | 2004 |
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
Topics: Antimetabolites, Antineoplastic; Breath Tests; Carbon Dioxide; Carbon Isotopes; Chromatography, High | 2004 |
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Brea | 2004 |
Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Combined Modality Th | 2004 |
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.
Topics: Aged; Base Sequence; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Case-Control | 2004 |
Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; | 2004 |
Determination of 5-fluorouracil in hospital effluents.
Topics: Electrophoresis, Capillary; Environmental Monitoring; Fluorouracil; Hospitals; Reference Standards; | 2004 |
A non-radioactive sensitive assay to measure 5-fluorouracil incorporation into DNA of solid tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA; Drug Screening A | 2004 |
EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; | 2005 |
Sphingosine kinase regulates the sensitivity of Dictyostelium discoideum cells to the anticancer drug cisplatin.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Animals; Antineoplastic Agents; Blotting, Western; Cisp | 2005 |
A new high-performance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure mo
Topics: Air Pollutants, Occupational; Calibration; Chromatography, High Pressure Liquid; Cyclophosphamide; F | 2005 |
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2005 |
Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
Topics: Atmospheric Pressure; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Deoxyuridin | 2005 |
Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fluo | 2005 |
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Cycle Proteins; Cell Membrane; Colorect | 2005 |
Improvement in 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd) concentration by 5-fluorouracil-polyethylene-glycol-liposomes in abdominal stop-flow: treatment of VX2 liver-tumor-bearing rabbits.
Topics: Animals; Biological Availability; Blood Flow Velocity; Chromatography, High Pressure Liquid; Disease | 2005 |
Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
Topics: Animals; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Dr | 2005 |
Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma; Case-Control Studies; Cisplat | 2005 |
Detection of infraclavicular lymph node metastases using ultrasonography in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Du | 2005 |
Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Diges | 2005 |
Validation of real-time reverse-transcription-polymerase chain reaction for quantification of capecitabine-metabolizing enzymes.
Topics: Capecitabine; Carboxylic Ester Hydrolases; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Dihy | 2006 |
High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma.
Topics: Chromatography, High Pressure Liquid; Fluorouracil; Humans; Reference Standards; Reproducibility of | 2006 |
Orotate phosphoribosyltransferase levels measured by a newly established enzyme-linked immunosorbent assay in gastric carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Ass | 2006 |
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Cell Line, Tumor; Clinical | 2006 |
Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; C | 2006 |
Raman, surface enhanced Raman spectroscopy, and DFT calculations: a powerful approach for the identification and characterization of 5-fluorouracil anticarcinogenic drug species.
Topics: Adsorption; Antineoplastic Agents; Colloids; Fluorouracil; Models, Chemical; Molecular Structure; Qu | 2005 |
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 2006 |
Immediate postoperative intraocular pressure measurements after trabeculectomy with releasable sutures.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; False Negative Reactions; Female; Fluorou | 2006 |
FDG-PET in colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinic | 2006 |
Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neopl | 2006 |
Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neopl | 2006 |
[Breast cancer in young women in the south of Tunisia].
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemot | 2006 |
The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Topics: Administration, Oral; Animals; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Colonic Neopla | 2007 |
Data acquisition for the histoculture drug response assay in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2007 |
A novel sandwich assay with molecular beacon as report probe for nucleic acids detection on one-dimensional microfluidic beads array.
Topics: Biological Assay; Cell Line, Tumor; Chemistry Techniques, Analytical; DNA; Drug Screening Assays, An | 2007 |
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
Topics: Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Caspases; Deoxycytidine; Drug Synergism; Flow C | 2007 |
[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Surviva | 2007 |
[A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoembryonic Antigen; Combined M | 2007 |
Translation, please.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2007 |
Management of advanced nodal disease following chemoradiation for head and neck squamous cell carcinoma: role of magnetic resonance imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
Fluorine-19 fast recovery fast spin echo imaging for mapping 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorine; Fluorouracil; Magnetic Resonance Spectroscopy; M | 2007 |
Fluorine-18-labeled 5-fluorouracil is a useful radiotracer for differentiation of malignant tumors from inflammatory lesions.
Topics: Animals; Colonic Neoplasms; Diagnosis, Differential; Female; Fluorine Radioisotopes; Fluorouracil; I | 2008 |
[Tissue distribution and excretion of 5-fluorouracil from indomethacin 5-fluorouracil-1-ylmethylester in rats].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Feces; Female; Fl | 2008 |
In-situ monitoring of breast cancer cell (MCF-7) growth and quantification of the cytotoxicity of anticancer drugs fluorouracil and cisplatin.
Topics: Antineoplastic Agents; Biological Assay; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor | 2008 |
Positron emission tomography in the detection of residual laryngeal carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, | 1995 |
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer.
Topics: Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost-Benefit | 1993 |
Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluoro | 1993 |
A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms | 1993 |
Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, | 1996 |
Endorectal ultrasound of T3 and T4 rectal cancers after preoperative chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; Follow | 1996 |
Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gas chromatography-mass spectrometry assay.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Gas Chromatography-Mass S | 1995 |
[Studies on the in vivo and in vitro chemosensitivity tests using human tumor xenografts].
Topics: Animals; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, An | 1995 |
Determination of 5-fluorouracil in human plasma by a simple and sensitive reversed-phase HPLC method.
Topics: Antimetabolites, Antineoplastic; Chemistry Techniques, Analytical; Chromatography, High Pressure Liq | 1996 |
Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy.
Topics: Animals; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Magnetic Resonance Spectrosc | 1996 |
Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass sp
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Drug Combinati | 1997 |
Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: application to a pharmacokinetic study.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Fluorouracil; Humans; Reprodu | 1997 |
Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma.
Topics: 5-Methylcytosine; Antimetabolites, Antineoplastic; Bromouracil; Chromatography, High Pressure Liquid | 1997 |
Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity.
Topics: Antimetabolites, Antineoplastic; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dihydro | 1997 |
Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1997 |
Simultaneous determination of 5-fluorouracil and its active metabolites in serum and tissue by high-performance liquid chromatography.
Topics: Animals; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Circadian Rhythm; Dr | 1997 |
Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation.
Topics: Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bone Marrow; Bone Marrow Cells | 1998 |
Spectrophotometric and spectrofluorimetric determination of fluorouracil in the presence of its degradation products.
Topics: Antimetabolites, Antineoplastic; Cobalt; Fluorouracil; Hydrogen-Ion Concentration; Sensitivity and S | 1998 |
A clinically applicable assay for tumoral thymidylate synthase combining reverse transcriptase-PCR and high-performance liquid chromatography.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Colorectal Neopl | 1998 |
Clinical applications of the histoculture drug response assay.
Topics: Antineoplastic Agents; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 1995 |
Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1999 |
Automated determination of 5-fluorouracil and its metabolite in urine by high-performance liquid chromatography with column switching.
Topics: Breast Neoplasms; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Fluorouracil; | 1999 |
Simple and sensitive determination of 5-fluorouracil in plasma by high-performance liquid chromatography. Application to clinical pharmacokinetic studies.
Topics: Chemical Precipitation; Chromatography, High Pressure Liquid; Drug Monitoring; Fluorouracil; Humans; | 1999 |
Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; CA-1 | 1999 |
A feasibility study of chemosensitivity assay by adhesive tumor cell culture system using biopsy specimens for gastric cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biopsy; Cisplatin; Doxorubicin; Drug S | 2000 |
Absorbable mesh sling prevents radiation-induced bowel injury during "sandwich" chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Case-Control Studies; Chemotherapy, Adjuvant; Dose-Response Relationshi | 2000 |
Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection.
Topics: Chromatography, High Pressure Liquid; Environmental Pollutants; Fluorouracil; Reference Standards; R | 2001 |
Simultaneous determination of flucytosine and fluorouracil in human plasma by high-performance liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Flucytosine; Fluorouracil; Humans; Reference Stan | 2001 |
CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoembryonic Antigen; Colorectal | 2001 |
Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colectomy; Colorec | 2001 |
Hydrophilic interaction chromatography using amino and silica columns for the determination of polar pharmaceuticals and impurities.
Topics: Acetamides; Acyclovir; Amines; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; F | 2001 |
Determination of 5-fluorouracil and 5-fluoro-2'-deoxyuridine-5'-monophosphate in pancreatic cancer cell line and other biological materials using capillary electrophoresis.
Topics: Antimetabolites, Antineoplastic; Buffers; Culture Media; Electrophoresis, Capillary; Fluorodeoxyurid | 2001 |
Does neoadjuvant chemoradiation downstage esophageal carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2001 |
Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene increases the sensitivity of esophageal cancer cells to 5-fluorouracil.
Topics: Adenoviridae; Animals; Drug Synergism; Escherichia coli; Esophageal Neoplasms; Fluorouracil; Mice; M | 2001 |
The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Proteins | 2001 |
Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon | 2002 |
[Prognostic factors in lymph node negative breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 2002 |
Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semi-automated HPLC-radioassay.
Topics: Adult; Aged; Asian People; Automation; China; Chromatography, High Pressure Liquid; Diagnostic Tests | 2002 |
Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Fluorouracil; Humans; Referen | 2002 |
Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 1992 |